

Human Medicines Regulations 2012

Advisory Bodies

Commission on Human Medicines

Annual Report 2024

Published July 2025



**Medicines and Healthcare products Regulatory
Agency**

**HUMAN MEDICINES REGULATIONS 2012
ADVISORY BODIES**

Commission on Human Medicines

**ANNUAL REPORT
2024**

**Laid before Parliament pursuant to
Part 2, Regulation 12(4) of
the Human Medicines Regulations 2012**



© Crown copyright 2025

**Published by the Medicines and Healthcare
products Regulatory Agency**

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

ISBN 978-1-8384147-4-0

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

Table of Contents

Foreword by the Minister of State for Health	9
Commission on Human Medicines	10
Annual Report - 2024	11
About the Commission on Human Medicines.....	11
Chair’s perspective on the year - Professor Sir Munir Pirmohamed	13
New active substances	13
Medicines that address unmet clinical need	16
Post-pandemic COVID vaccines.....	17
Extension of use of approved medicines	18
The Early Access to Medicines Scheme (EAMS)...	21
Orphan designations.....	21
Reclassification of medicines.....	23
Advice on Established/Generic medicines.....	24
Policy/Strategy Advice	25
Advice to Secretary of State for Health and Social care	29
Backlog Clearance	29
Safety of Medicines.....	32
Involving patients’ views at the CHM	33
Highlights of our 2024 achievements.....	36

Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2024.....	39
Membership	40
Costs	41
Code of Practice for the Commission on Human Medicines and other expert advisory committees.....	43
Membership of the Commission on Human Medicines (CHM).....	45
CHM Co-opted Members, Invited Experts and Observers.....	51
Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)	61
Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG).....	66
Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)	69
Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)	71
Membership of the Infection Expert Advisory Group (IEAG)	74
Membership of the Medicines for Women’s Health Expert Advisory Group (MWHEAG).....	77

Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)	81
Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)	84
Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)	87
Membership of the Pharmacovigilance Expert Advisory Group (PEAG)	92
Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)	96
Membership of the CHM’s Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG)	99
Membership the Real World Data Expert Working Group (RWD EWG)	106
Membership of the Valproate Epigenetics Expert Working Group (VEEWG)	109
Membership of the CHM’s Valproate Implementation Working Group (VIEWG)	112
ANNEX A - DECLARATION OF INTERESTS	116

Foreword by the Minister of State for Health

It gives me great pleasure to present the annual reports for 2024 of the Human Medicines Regulations Advisory Bodies: The Commission on Human Medicines. These reports include a record of members' interests in the relevant industry as per the Conflicts of Interest Code of Practice.

On behalf of all Health Ministers, I would like to thank the Chairs and Members of the Commission and all those who contribute to their many Expert Advisory Groups and Expert Working Groups whose professional expertise, commitment and hard work plays a vital role in ensuring that the medicinal products we take continue to meet the highest standards of safety, quality and efficacy.

Karin Smyth MP

Commission on Human Medicines

Annual Report - 2024

About the Commission on Human Medicines

The Commission on Human Medicines (CHM) is an advisory non-departmental public body, sponsored by the [Department of Health and Social Care](#) (DHSC).

The CHM was established in 2005 to advise ministers and the Licensing Authority, [Medicines and Healthcare products Regulatory Agency](#) (MHRA), on the safety, efficacy and quality of medicinal products.

The functions of the CHM are set out in Regulation 10 of the Human Medicines Regulations 2012 (SI 2012/1916). This report presents a summary of the work undertaken by CHM in 2024.

The functions of the CHM are:

- to advise the Health Ministers and the Licensing Authority (LA) on matters relating to human medicinal products including giving advice in relation to the safety, quality and efficacy of human medicinal products where either the Commission thinks it appropriate or where it is asked to do so;

- to consider those applications where the LA has a statutory duty to refer to the CHM or chooses to do so;
- to consider representations made (either in writing or at a hearing) by an applicant or by a licence or marketing authorisation holder in certain circumstances;
- to promote the collection and investigation of information relating to adverse reactions to human medicines for the purposes of enabling such advice to be given.

Chair's perspective on the year - Professor Sir Munir Pirmohamed

The CHM depends heavily on the dedication, knowledge and experience of its experts and the considerable efforts from all experts, including lay representatives and invited patient experts, are greatly appreciated and valued. The immense contribution of the CHM's experts has ensured advice to the MHRA and the Health Ministers is based on rigorous examination of scientific data leading to regulatory decisions translated effectively into clinical practice, with a direct benefit to patients.

New active substances

In 2024, the CHM continued to carefully consider the data on quality, efficacy & safety of a number of new active substances and after detailed deliberations, advised the MHRA on the approvability of these new medicines. Some examples of new medicines include:

- Two treatments for early Alzheimer's Disease - **Lecanemab** (Leqembi), a monoclonal antibody targeting the beta-amyloid deposits for treatment of adult patients with early stages of Alzheimer's disease who have either no copies or only one copy of the apolipoprotein E4 gene (ApoE4), and

Donanemab (Kisunla), another monoclonal antibody acting on a similar target. These were the first two treatments authorised for the treatment of Alzheimer's disease where the treatments have the potential to alter the course of the disease progression. The CHM took inputs from physician experts and patient representatives in giving their final advice for these treatments.

ApoE4 homozygous patients who received lecanemab/donanemab were at higher risk of developing adverse effects. In considering the magnitude of benefit on slowing the progression of the disease, the CHM advised that the risk:benefit of lecanemab/donanemab was favourable in the patients who were ApoE4 non-carriers or heterozygous but not in the homozygous group, and therefore testing for the ApoE4 gene should be carried out before treatment. Approval of these products was dependent on a robust pharmacovigilance approach, including a controlled access programme.

- **Imdelltra** (tarlatamab), a medicinal product indicated for the treatment of adult patients with advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.

- **Tauvid** (Flortaucipir), a new diagnostic radiopharmaceutical product used in a PET scan for adult patients showing signs of cognitive impairment to diagnose Alzheimer's disease.
- **Fruzaqla** (Fruquintinib), a medicine for the treatment of adult patients with metastatic colorectal cancer (CRC) when other treatments have not worked.
- **Vyloy** (Zolbetuximab), a monoclonal antibody that targets the Claudin 18.2 (CLDN18.2) protein found in the stomach lining and is approved for the treatment of adult patients with gastric or gastro-oesophageal junction cancer who are positive for the CLDN18.2 and negative for the human epidermal growth factor receptor 2 (HER2) proteins.
- **Iqirvo** (Elafibranor), a medicine for the treatment of adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).
- **Truqap** (Capivasertib) is an AKT kinase inhibitor approved for the treatment of patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer which has one or more abnormal PIK3CA, AKT1 or PTEN gene and does not respond to other anti-hormonal based therapies. Capivasertib is authorised for use with fulvestrant in these patients.

Medicines that address unmet clinical need

Some of the new medicines were in therapeutic areas where there was a great unmet medical need and, in such cases, the CHM advised the MHRA on granting either a conditional marketing authorisation (CMA) or a marketing authorisation under exceptional circumstances, where the comprehensive evidence on efficacy and safety was not yet available. This facilitated early access of new medicines to patients. Some examples where medicines were approved under a CMA include:

- **Filspari** (Sparsentan) works by blocking endothelin and angiotensin and lowers the protein in the urine and thereby helps to slow down the progression of the kidney damage in Berger's disease, where Immunoglobulin A (IgA) builds up in the kidneys. Filspari was also granted an orphan medicine designation as the condition is rare.
- **Eqjubi** (Sugemalimab), a monoclonal antibody targeting the programmed death-ligand 1 (PD-L1) for the treatment of adult patients with non-small cell lung cancer.
- **Wainzua** (Eplontersen) for the treatment of adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare

progressive condition that runs in families and is caused by a protein called transthyretin.

Eplontersen works mainly by lowering the amount of TTR protein made by the liver. As a result, there is less TTR protein in the blood to form amyloid deposits and cause neuropathy.

- **Joenja** (Leniolisib phosphate) for the treatment of a rare immune disease known as activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents aged 12 years and over. Joenja was granted an orphan designation as this condition is rare.

Post-pandemic COVID vaccines

Although the public health emergency due to COVID has passed, there is still a need for COVID vaccines and therapeutics to prevent and treat infections with the different emerging strains of the COVID virus particularly in high risk populations. In this regard, the CHM has advised on the following:

- **Nuvaxovid JN.1 vaccine** is a line extension of the existing Nuvaxovid COVID19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and adolescents aged 12 years and older.

Similarly, a Nuvaxoid vaccine targeting Omicron XBB1.5 subvariant was also approved.

- **Spikevax JN.1 vaccine** is a line extension of the Spikevax COVID-19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and children aged 6 months and above.
- **Comirnaty JN.1 vaccine** is a line extension of the existing Comirnaty COVID 19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and children aged 6 months and above.
- **Comirnaty KP.2 vaccine** is a line extension of the existing Comirnaty COVID 19 vaccine product and provides immunity against COVID by targeting the KP.2 subvariants and is licensed for use in adults.

Extension of use of approved medicines

The CHM has also advised on the safety and effectiveness of already approved medicines for use in new indications or continued approvability of medicines approved under conditional marketing authorisation based on evaluation of the emerging evidence on benefit and safety. Some examples of such applications include:

- **Wegovy** (Semaglutide), a GLP-1 receptor agonist was approved for a new indication to reduce the risk of overweight and obese adults suffering serious heart problems or strokes. This was previously approved for use in treatment of obesity and for weight management, but with this variation, this became the first weight loss drug prescribed to prevent cardiovascular events in overweight and obese patients with established cardiovascular disease.
- **Vabysmo** (faricimab), a humanised bispecific antibody that inhibits both angiopoietin-2 and vascular endothelial growth factor A (VEGF-A) was approved for a new indication in treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). This was previously approved for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
- **Mavenclad** (cladribine) – widening of the indication to include relapsing forms of multiple sclerosis with active disease as defined by clinical or imaging features. The indication was previously restricted for treatment of highly active relapsing multiple sclerosis.
- **Ayvakyt** (Avapritinib) was approved in a new indication for the treatment of adult patients with advanced systemic mastocytosis including

aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm or mast cell leukaemia. Previously it was approved solely for the treatment of unresectable or metastatic gastrointestinal stromal tumour.

- **Metformin** is a biguanide with antihyperglycaemic effects and also has other effects including lowering hyperandrogenism due to polycystic ovarian syndrome. It was approved in a new indication for ovarian stimulation to support conception in women with polycystic ovarian syndrome. The approved indications of metformin previously were mainly for treatment of type 2 diabetes mellitus.
- **Blinicyto** (Blinatumomab) was approved for a new indication for the treatment of patients with CD19-positive B-precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase. It was previously authorised for other stages of B-cell ALL.
- **Imfinzi** (Durvalumab) was approved for a new indication for use in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR gene mutations or ALK rearrangements. It was previously approved for treatment of locally advanced, unresectable NSCLC and other cancers such as

small cell lung cancer, biliary tract cancer, hepatocellular carcinoma and endometrial cancer.

The Early Access to Medicines Scheme (EAMS)

The Early Access to Medicines Scheme (EAMS) helps to give people with life threatening or seriously debilitating conditions early access to new medicines that do not yet have a marketing authorisation, where there is a clear unmet medical need. The CHM gave preliminary advice to the MHRA on two EAMS applications, asking the MHRA to seek more information and justification from the applicants before a final advice can be provided.

Orphan designations

The MHRA offers incentives in the form of market exclusivity and full or partial refunds for marketing authorisation fees to encourage the development of medicines in rare diseases. The CHM advises the MHRA on orphan designation applications and whether the medicine, its effects and the medical condition meets the criteria. The CHM considered and discussed the eligibility of products for orphan designation and over the last year, advised on the grant of orphan designation for products which target rare diseases. Some examples of

the products on which the CHM advised the orphan designation include:

- **Agamree** (vamorolone) was approved for treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. This is a rare condition with a high unmet need and this product received a conditional marketing authorisation as an orphan medicine.
- **Andembry** (Garadacimab) was approved for the routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older. This product was evaluated for fulfilment of orphan designation criteria and although this was a rare condition, there were other treatments available for this condition and based on the CHM's advice, the applicant proceeded to a marketing authorisation approval without orphan designation.
- **Iqirvo** (Elafibranor) tablets were authorised for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. As this is a rare condition, the product was authorised as an orphan medicine.
- **Duvyzat** (Givinostat) is another medicine indicated for the treatment of patients aged 6 years of age and older with all genetic variants of

Duchenne muscular dystrophy. It received a conditional marketing authorisation as an orphan medicine.

Reclassification of medicines

Reclassification of medicines involves switching the legal status of medicines between Prescription-only medicines (POM), Pharmacy medicines (P) and General Sales List medicines (GSL). New medicines are generally approved as 'prescription-only medicines', but over time, growing confidence in the medicine's role and improved understanding of its side effects can lead to switches to Pharmacy or General Sales List which empower patients' ability to self-care and alleviate the demand for NHS services. The CHM considered the evidence and justifications supporting the applications for reclassification and advised on reclassification of medicines; examples include:

- POM to P reclassification of **Ovesse** (estriol) vaginal cream for treatment of vaginal atrophy associated symptoms due to oestrogen deficiency of menopause in women aged 50 years and above who have not had a period for at least 1 year.
- POM to P reclassification of melatonin indicated in adults for short-term treatment of jet lag.

- POM to P reclassification of **Dymista** (azelastine hydrochloride, fluticasone propionate) for the relief of symptoms of moderate to severe seasonal allergic rhinitis in adults if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
- Review of access to loperamide through General Sales and as Pharmacy medicines – consideration of originator marketing authorisation holder (MAH) written representations to the CHM.

Advice on Established/Generic medicines

The CHM also advised on the approvability of several established medicine applications. Established medicines constitute the majority of the medicines used in the UK so the MHRA needs to ensure patients and prescribers in the UK have access to safe and effective medicines of good quality. The advice from CHM in relation to such products included a wide range of topics, such as the balance of the weight of benefits as compared against the risks to the acceptable intake levels of nitrosamine impurities that could be permitted in different medicines. In addition, the CHM advised on the implementation of the Synapse Article 31 referral recommendations with respect to the bioequivalence of critical products for the UK for which companies can be given time to submit new bioequivalence studies.

Policy/Strategy Advice

The CHM also provided advice to the MHRA in shaping the regulatory strategies for the Innovative Licensing and Access Pathway (ILAP). The CHM discussed the proposed revisions for a refreshed ILAP criteria and Target Development Profile (TDP) and provided advice to the MHRA on their draft proposals.

The CHM discussed the clinical trials “notification” framework, which extended the criteria for the notification scheme for initial clinical trial applications and introduced criteria for notification of certain clinical trial substantial amendments. The CHM discussed the proposals and provided advice on the implementation steps in terms of piloting, reviewing and modifying the notification framework as appropriate. Whilst the CHM supported the proposed notification scheme’s extended criteria, the need to focus on the safety of the trial participants was emphasised, as it should be the main consideration in the proposals and the future review. Based on the CHM’s advice, a new clinical trials framework was developed for the UK by the MHRA.

The CHM also held a session on lessons learned from the experience of dealing with the COVID-19 pandemic. A number of positives were identified that should be carried forward such as:

- Establishment of Expert Working Groups which allowed the CHM to receive inputs from a wide range of disciplines.
- Clear distinction between the information gathering part of the meeting, where the invited attendees could contribute, and the decision making part, where the invited attendees would not be present, thus maintaining the independence of the CHM.
- Rolling submission of data and CHM access to raw data was useful in a public health emergency, although this could be overwhelming and would need more signposting in the future.
- Prompt publications of meeting minutes for transparency with additional resource available for this activity in case of a future health emergency.

Some issues were identified that need to be addressed such as:

- Difficulty of operating two different regulatory regimes, one for Great Britain and one for Northern Ireland.

- Poor interaction with the European Medicines Agency (EMA) and it was felt that more interaction with the EMA would have been helpful.
- Difficulties in getting specific detailed case-information on adverse events of interest to inform decision making. It was agreed that systems for gathering medical information from individual cases need to be improved through improved collation and linkage of healthcare databases to support timely identification of adverse events.

In order to support the development of personalised medicines the CHM also recommended the conversion of the Cancer Vaccine Expert Working Group (EWG) which was established in March 2023 to a Highly Personalised Medicines Expert Working Group from May 2024. This new EWG has a broader remit with updated Terms of Reference that covers all personalised medicines rather than only cancer vaccines. The CHM advised the expansion of this group to include additional relevant experts capable of advising on the broader remit.

Additionally, the CHM discussed and advised on the following subjects:

- Absence of dose counters on short-acting Beta-agonists.
- Biosimilars naming guidance.

- Draft guidance for developers of individualised mRNA cancer immunotherapies.
- Publication of “pharmacokinetic data during pregnancy” on the MHRA website and provided inputs based on test summaries for specific medicines such as lamotrigine, phenytoin, levetiracetam and carbamazepine. The CHM was supportive of this approach to disseminate useful information to prescribers and patients. The CHM provided feedback on simplifying the language in the summary to enable delivery of the key messages to lay-people.

Advice to Secretary of State for Health and Social care

The Secretary of State for Health and Social Care and the Minister of Health for Northern Ireland jointly consulted [directly] with the CHM for advice on the known benefits and risks of drugs used for the purposes of gender incongruence and/or gender dysphoria, under the care of private or non-UK prescribers. The CHM's report on the proposed changes to the availability of puberty blockers was finalised on 13 Nov 2024 and published on 24 Jan 2025.

This is available at:

<https://www.gov.uk/government/publications/chms-report-on-proposed-changes-to-the-availability-of-puberty-blockers>

Backlog Clearance

The CHM played a key role in addressing the backlog of clinical trial authorisation applications and marketing authorisation applications built up at the MHRA following the UK's withdrawal from the European Union and the re-organisation at the MHRA, by providing expert advice and recommendations in the following areas:

- Clinical Trials

- Supported the development of the Notification Criteria based on a risk proportionate approach for both initial applications and amendments, where the applications that meet these criteria could be considered approved upon notification to the MHRA.
- Helped to refine the criteria of the notifiable trials before inclusion in the statutory instrument on clinical trials regulations that was laid before Parliament.

- Marketing Authorisation Applications

- The CHM, with the help of one of its main expert advisory groups (EAG), the Chemistry, Pharmacy and Standards (CPS) EAG, reviewed an increased number of papers ranging between 25-40/month (as compared to the previous average around 10 applications) on abridged applications of generic medicinal products with known active substances over the latter part of last year, which helped in clearing the backlog in established medicines applications. This was a significant challenge to all involved to ensure that consistent levels of deep and rigorous scientific analysis of these

applications were maintained while clearing the backlog.

- The main issues in these applications were related to quality or joint quality/clinical, which was the expertise of the CPS EAG. The members of the CPS EAG worked in small teams over extended meeting periods to review the increased number of applications, and this provided the necessary assurance to the CHM to consider and endorse as appropriate, the issues identified in these applications expeditiously.

Safety of Medicines

The CHM advised on a range of product specific issues relating to the safety of medicines over the course of the year, including:

- Newly analysed data on the reproductive risks associated with **sodium valproate** and the potential for epigenetic effects with advice of the Valproate Epigenetics Expert Working group taken into consideration.
- Recommendations of the Valproate Epigenetics Expert Working Group on the updates to the **valproate** licence and need for further research.
- Expansion of the Terms of Reference and membership of an antidepressant risk minimisation expert working group looking at how the risk of suicidal behaviours and sexual dysfunction where symptoms continue are communicated in patient leaflets and ways risk minimisation can be improved.
- Safety signals associated with and plans for the ongoing monitoring of the safety of the **RSV vaccine**.
- Risk minimisation improvements for **paracetamol** including the consideration of further pack size restrictions.

- Addition of psychological adverse effects to the **Kaftrio** product information.
- Plans for independent review of the Plasma-derived medicinal products in the context of variant Creutzfeldt-Jakob disease (CJD).

The CHM provided advice on risk management plans for all applications for marketing authorisation assessment for all new active substances and all known active substances.

Involving patients' views at the CHM

Patient views are essential in regulatory decision-making on the safety of medicines. In 2024, the patient voice, and their lived experience, was represented through a variety of patient engagement strategies including inviting patients and their representatives to the CHM meeting, through patient charity engagement and through the consideration of written input from patients in all formats including Yellow Card reports and direct correspondence.

Following the publication of the CHM Isotretinoin Implementation Expert Advisory Working Group (IIEAWG) on 31 October 2023, the CHM reviewed initial feedback from stakeholders involved in the

implementation of the new regulatory requirements for **isotretinoin**. As a result of this stakeholder input the CHM advised on the insertion of an addendum to the IIEAWG report in order to facilitate safe implementation of the new recommendations.

The CHM, as per the terms of reference, also has a duty to ensure that information relating to adverse reactions was collected and scrutinised throughout 2024. The CHM provided advice on the trends and themes in the Pharmacovigilance statistics presented at every meeting and on specific new emerging safety signals from Yellow Card data. The CHM considered and provided advice on the UK implications of any safety related recommendations for product information highlighted by the EU Pharmacovigilance Risk Assessment Committee minutes discussed at each meeting.

The CHM take assurance that the MHRA has systems in place for reporting of suspected adverse drug reactions and for review of these and other reports. However, the CHM continues to have an important role in giving independent advice on these safety data where needed. In 2024, 101,000 adverse drug reactions reports were received by the MHRA; 24% from patients, 32% from Industry and 43% from healthcare professionals.

Highlights of our 2024 achievements

Authorisation of safe and effective new medicines is central to advancing public health as they offer new opportunities for treating certain diseases. In 2024:

The CHM reviewed and advised on **442** papers over 12 scheduled monthly meetings, the details of these are:

Type of Product

360 papers were on Chemical products including 1 radiopharmaceutical product and 30 products with new active substances	32 papers were not related to any specific medicinal products	50 papers were on Biological products
--	--	--

Groups seeking CHM advice

391 of the papers were by the licensing (Healthcare Quality and Access) group. This included:	44 of the papers were led by the post-licensing (Safety and Surveillance, S&S) group, which included 12 papers on	7 papers were by other group including 3 from Science, Research & Innovation group and 4 from the
--	---	--

* The licensing authority seeks advice from the CHM by the form of a "paper". A paper may cover a number of products, either pre-licensing or post-licensing, to ask for CHM's preliminary or final advice. Preliminary Advice is CHM's provisional opinion on the product concerned, as described in Schedule 11 of the HMR. CHM's recommendation is final following representations made by the applicant (Sch 11 of the HMR).

- **384*** papers on applications for medicinal products (including new actives and known active substances) including **128** Risk Management Plan assessments by the S&S group
- **7** papers on general topics

Pharmacovigilance Department of
 Statistics (Yellow Health & Social
 Card data) and **11** Care
 papers on PRAC
 highlights

* These **384** papers concerned application for **641** medicinal products, as some papers would cover multiple medicinal products of different strengths.

Stage of advice

256 papers were preliminary advice on applications

128 papers were final advice on applications

58 papers were on strategy and/or process

The above papers included **2** papers under the Early Access to Medicines Scheme

Additionally, **1** ad-hoc/extraordinary meeting was held in March by the CHM where they provided advice on two

applications for medicinal products, one biological product and the other a chemical medicinal product.

Once a medicine has been authorised, the MHRA continuously monitors the quality, safety and efficacy of the medicine to keep patients safe.

Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2024

CHM, Expert Advisory Groups and Expert Working Groups	Abbrev.	Papers Considered and Advice Given	
		by meeting	by writing
Commission on Human Medicines	CHM	444	1
Chemistry, Pharmacy and Standards	CPS EAG	105	-
Clinical Trials, Biologicals & Vaccines	CTBV EAG	2	6
Pharmacovigilance	P EAG	35	1
Cardiovascular, Diabetes, Renal, Respiratory and Allergy	CDRRA EAG	6	3
Gastroenterology, Rheumatology, Immunology & Dermatology	GRID EAG	4	1
Paediatric Medicines	PM EAG	20	1
Oncology and Haematology	OH EAG	13	1
Neurology, Pain & Psychiatry	NPP EAG	4	4

Medicines for Women's Health	MWH EAG	12	3
Highly Personalised Medicines Expert Working Group		14	-
Valproate Epigenetics Expert Working Group		1	-
Valproate Implementation Expert Working Group		7	-
Total Papers Considered and Advice Given		688	

Summary reports based on the minutes of each meeting from the CHM's Expert Advisory Groups are published on the [GOV.UK](https://www.gov.uk) website.

Membership

Chair and Members of the Commission on Human Medicines are appointed under Regulation 9 of the Human Medicines Regulations 2012, and are expected to abide by the [Code of Conduct for Board Members of Public Bodies](#) and [Governance Code for Public Appointments](#), as part of their terms and conditions of appointment. Chairs and Members of the expert advisory groups and working groups are also expected to abide by the [Code of Practice for Scientific Advisory Committees](#).

The CHM has 20 members (including the Chair) appointed by Ministers and meets 12 times a year for up to two days. In 2024, eight of the 12 meetings were two-day meetings. The work of the CHM is supported by ten established Expert Advisory Groups (EAGs) as well as three Expert Working Groups (EWG) comprising of 179 experts.

EWGs are created by the CHM, in discussion with the Licensing Authority, to advise the CHM on particular specialist issues. The CHM wishes to record its gratitude and appreciation of the valuable work of its Expert Advisory Groups and Working Groups. Details of members of the CHM, its expert advisory groups and working groups are listed in this report.

Costs

Commissioners are entitled to claim an attendance fee of £325 per day or a Chair's fee of £500. Expert Advisory Group members are entitled to claim an attendance fee of £200 or a Chair's fee £325. Travel and subsistence are also payable within standard Department of Health & Social Care guidelines.

If you are interested in learning more about CHM's you can find further information on the Gov.uk website:

<https://www.gov.uk/government/organisations/commission-on-human-medicines>

Code of Practice for the Commission on Human Medicines and other expert advisory committees

All chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees are required to declare any personal and non-personal interest, or any significant interests held by close family or friends, which may be reasonably perceived to influence their judgement in performing their functions and obligations.

Furthermore, all chairs and members must declare their interest in any items being discussed at meetings and will declare any new conflict of interest at the earliest opportunity in advance of the next meeting they attend and openly at that next meeting. These are recorded in the meetings' minutes. Where a member declares a potential conflict at meetings, it is recorded in the minutes and the member's subsequent involvement is dealt with depending on the topic, forum and type of interest or conflict, in accordance with the Code of Practice.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

The Code of Practice is published on:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103036/2022.09.07_The_Code.pdf

The list of declared interests for chairs and members of CHM (and EAGs, EWGs and ad-hoc groups) is available below.

Membership of the Commission on Human Medicines (CHM)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Vice Chair	Professor Steven Cunningham MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Lay Member	Mrs Julia Cons	
Lay Member	Mr David Crundwell	

Member	Professor Amanda Adler MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Member	Professor Paul I Dargan MB BS FRCP Edin FACMT FRCP ERT FAACT FEAPCCT FBPhS MAE FCRaz FRSB	Consultant Physician and Professor of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London Professor of Clinical Toxicology, King's College London
Member	Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Member	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Member	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian

		Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor David Moore MBCChB MD MSc DTM&H	Professor of Infectious Diseases and Tropical Medicine, London School of Hygiene and Tropical Medicine and Consultant in Infectious Diseases and Tropical Medicine, Hospital for Tropical Diseases, University College London Hospital
Member	Dr Gerri Mortimore PhD; MSc Advanced Practice; PgCert (IPPE); BA(Hons) Health Studies; iLM. RGN; NMP; FHEA	Associate Professor in Advanced Clinical Practice; NICE Nurse Expert Advisor
Member	Professor Sandosh Padmanabhan MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow

Member	Professor Poulam Patel¹ PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Member	Professor Rui Providencia MD PhD	Institute of Health Informatics Research, University College London. Consultant Cardiologist & Cardiac Electrophysiologist, Barts Health NHS Trust
Member	Dr Vanessa Raymont MBChB MSc MRCPsych	Senior Clinical Researcher, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust

¹ Reappointed 05/07/2024

Member	Professor Marc Turner² MB ChB PhD MBA FRCP FRCPath FRSE	Director, Scottish National Blood Transfusion Service
Member	Professor Heather M Wallace PhD FRCPath FRSC FRSB FBTS FBPhS ERT	Professor Emerita of Biochemical Pharmacology and Toxicology, University of Aberdeen
Member	Professor Christopher Weir³ BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh
Member	Professor Anthony Williams BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust

² Reappointed 05/07/2024

³ Reappointed 05/07/2024

Member	Dr Martin Wilson MB ChB, MPhil (Glasgow), FRCP(Edin)	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness
---------------	---	--

CHM Co-opted Members, Invited Experts and Observers

Post	Name and title	Affiliations (if applicable)
Co-opted Member (May-Dec)	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Co-opted Member (Jun)	Dr Majella Lane BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Co-opted Member (Nov)	Dr Jonathan Lord MD FRCOG FHEA	Consultant Obstetrician and Gynaecologist, Royal Cornwall Hospitals NHS Trust
Invited Expert (Jan)	Prof Jon S. Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci	Deputy Vice-Chancellor (Research & Enterprise), St. George's, University of London
Invited Expert (Jan)	Professor Richard J C Gilson MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre

		for Clinical Research in Infection & Sexual Health
Invited Expert (Jan, Mar, Jul)	Professor Gillian M Hawksworth MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at University of Huddersfield & Past President of the RPSGB
Invited Expert (Jan)	Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPATH	National Clinical Director, Blood and Infection Programme of Care, NHS England, Consultant Immunologist, Lead for Clinical Immunology, Oxford University Hospitals, John Radcliffe Hospital, Oxford
Invited Expert (Jan)	Ms Rebecca Penzer-Hick	Senior Clinical Lecturer, Centre of Postgraduate Medicine and Public Health Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire

Invited Expert (Jan)	Professor Stuart H Ralston MB ChB MD FRCP FFPM (Hon) FMedSci FRSE	Versus Arthritis Professor of Rheumatology, Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh
Invited Expert (Jan, Dec)	Dr Jane Ravenscroft	Consultant Dermatologist at Nottingham University Hospital and Honorary Assistant Professor at the Centre for Evidence Based Dermatology, Nottingham and Chair of the Isotretinoin Implementation EWG
Invited Expert (Jan)	Professor Sobha Sivaprasad MBBS MS DM FRCS FRCOphth	Consultant Ophthalmologist, Moorfield's Eye Hospital
Invited Expert (Jan, Feb, Sep, Dec)	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London

Invited Expert (Feb)	Dr Robert Andrews	Senior Lecturer FHEA, Data Hub at Heath, Cardiff
Invited Expert (Feb)	Dr Brendan Fish BSc PhD	Director of Biologics & RNA Centre of Excellence
Invited Expert (Feb, Apr, May, Jul)	Professor Robert Howard	Professor of Old Age Psychiatry, Division of Psychiatry, University College London
Patient Expert (Feb)	Patient Expert 1	
Invited Expert (Apr)	Dr Pawan Gupta FRCA, MD	Consultant Anaesthetist & Hon. Clinical Associate Professor Leeds Teaching Hospitals / University of Leeds / Malignant Hyperthermia Unit

Invited Expert (Apr)	Professor Darragh Murnane PhD BSc (Pharm) PhD MRPharmS	Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire
Invited Expert (Apr, May)	Professor James Rowe	Professor of Cognitive Neurology, University of Cambridge
Invited Expert (Apr)	Mr Mark Stringer	Regional Quality Assurance Specialist East of England
Invited Expert (May)	Dr Rasha Al-Qurainy MD FRCP MSc	Clinical Lead and Consultant in Palliative Medicine, Camden, Islington and UCLH Palliative Care Service, Central and Northwest London NHS Foundation Trust
Patient Experts (Jun)	Patient Experts 2	

Invited Expert (Jun)	Professor Giovanni Baranello MD PhD	Professor of Paediatric Neuromuscular Disorders, Honorary Consultant in Paediatric Neuromuscular Diseases, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital NHS Foundation Trust
Invited Expert (Jun, Sep)	Professor Sobha Sivaprasad MBBS MS DM FRCS FRCOphth	Consultant Ophthalmologist, Moorfield's Eye Hospital
Invited Expert (Jul)	Professor William (Bill) Newman MA PhD FRCP FMedSci	Professor of Translational Genomic Medicine, University of Manchester
Invited Expert (Aug)	Professor Philip (Phil) Hannaford FRSE	Emeritus Professor of Primary Care University of Aberdeen
Invited Expert (Aug)	Professor Chris Fox	Clinical Professor in Haematology Faculty of Medicine & Health Sciences, University of Nottingham

Invited Expert (Sep)	Dr Indi Bannerjee	Consultant Paediatric Endocrinologist, Central Manchester & Manchester Children's Foundation Trust
Invited Expert (Sep)	Professor Tim Cheetham	Professor of Clinical Paediatric Endocrinology, Newcastle upon Tyne Hospitals and honorary consultant paediatrician at Royal Victoria Infirmary, Newcastle upon Tyne
Invited Expert (Oct)	Professor Gary Cook MBBS MSc MD FRCR FRCP	Professor of Molecular Imaging / Honorary Consultant Physician, King's College London and Guy's & St Thomas' Hospitals
Invited Expert (Nov)	Professor Chris Goldring BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.
Invited Expert (Nov)	Professor Ben Burton	Honorary Professor, University of East Anglia, Consultant Ophthalmologist, James Paget University Hospital

		President of the Royal College of Ophthalmologists
Invited Expert (Nov)	Dr Livia Martucci MBBS PhD MRCPsych	Consultant Perinatal Psychiatrist, South London and Maudsley NHS Foundation Trust (SLaM), Chair of the Perinatal Faculty at RCPsych
Patient Expert (Nov)	Patient Expert 3	
Patient Expert (Dec)	Patient Expert 4	
Patient Expert (Dec)	Patient Expert 5	
Invited Expert (Dec)	Dr Piya Sen Gupta	Consultant in in diabetes and endocrinology, Guy's & St Thomas' NHS Foundation Trust

Invited Expert (Dec)	Dr Tamara Griffiths	President, British Association of Dermatologists
Invited Expert (Dec)	Professor Michael Arden-Jones	Vice-President of BAD
Observers	Representatives of the Department of Health and Social Care (DHSC) have observed the following meetings:	
	<ul style="list-style-type: none"> • Jan, Sep, Oct 	
Observers	Officials from National Institute for Health and Care Excellence (NICE) have observed the following meetings:	
	Apr, May, Jun, Jul, Aug, Sep, Oct, Nov, Dec	
Observers	Officials from United Kingdom Health Security Agency (UKHSA) have observed the following meetings:	
	<ul style="list-style-type: none"> • Sep, Oct 	
Observers	Officials from Devolved Nations Administrations (Wales) have observed the following meetings:	
	<ul style="list-style-type: none"> • Sep, Oct 	

Observers	Officials from Devolved Nations Administrations (Scotland) have observed the following meetings: <ul style="list-style-type: none"> • Feb, Sep, Oct
Observers	Officials from Health Canada have observed the following meetings: <ul style="list-style-type: none"> • Nov
Observers	Officials from Therapeutic Goods Administration (TGA), Australia, have observed the following meetings: <ul style="list-style-type: none"> • Nov

Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Amanda Adler MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Dr Amine Boualem MD MRCGP PGDip(Diabetes) AHEA	GP Partner, East Barnwell Health Centre, Cambridge
Member	Professor Mark Evans Bsc MB BS MD FRCP	Professor of Diabetic Medicine, University of Cambridge and Consultant Physician, Cambridge University Hospitals
Member	Professor William G. Herrington MA(Cantab) MBBS(London) MD(Cantab) FRCP(London)	Professor of Trials and Epidemiology of Kidney Disease. Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford; Honorary Consultant Nephrologist, Oxford Kidney Unit

Member	Dr Patrick Holmes MB BS MSc MRCGP	GP Partner St. George's Medical Practice, Darlington
Member	Dr Wajid Hussain BSc (Hons) MB ChB (Hons) MSc FRCP	Consultant Cardiologist, Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas' NHS Foundation Trust
Member	Dr Hassan Kahal ⁴ PhD, FRCP, PG CertMedEd, SCOPE,	Consultant in Diabetes, Endocrinology, and Obesity Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol
Member	Professor Sandosh Padmanabhan MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor Patrick Mark MB CHB (Hons) PhD FRCP (Glasg)	Professor of Nephrology & Honorary Consultant Nephrologist, University of Glasgow and Glasgow Renal and

⁴ Appointed 02/12/2024

		Transplant Unit, Queen Elizabeth University Hospital, Glasgow
Member	Professor Theresa McDonagh BSc (Hons), MB ChB (Hons), MD (Distinction), FRCP, FESC, FHFA	Consultant Cardiologist, King's College Hospital, London & Professor of Heart Failure King's College, London
Member	Dr Shuaib Nasser MA MBBS MD FRCP	Consultant Allergist and Respiratory Physician, Head of Allergy Cambridge University Hospital NHS Foundation Trust, Cambridge
Member	Professor John Petrie ⁵ BSc(Hons) MBChB PhD FRCP(Glasg) FRCP(Edin)	Professor of Diabetes & Director of Glasgow Clinical Trials Unit, University of Glasgow
Member	Professor Anita K Simonds MD FRCP FERS	Professor Emeritus of Respiratory and Sleep Medicine, National Heart and Lung Institute, Imperial College, London

⁵ Appointed 02/12/2024

		& Honorary Consultant Respiratory and Sleep Physician, Royal Brompton & Harefield Hospital, Sydney Street, London, Harveian Librarian, Royal College of Physicians, London
Member	Dr Rona Smith⁶ MA(Cantab) MB BChir(Cambridge) MD(Cantab) MRCP(London)	Associate Professor of Nephrology, University of Cambridge; Honorary Consultant in Nephrology and Vasculitis, Cambridge University NHS Foundation Trust.
Member	Professor Michael Steiner MB BS BSc MD FRCP	Professor in Respiratory Medicine and Honorary Consultant, Dept of Respiratory Science, University of Leicester

⁶ Appointed 02/12/2024

Member	Professor Sarah Wild⁷ MB BChir MSc PhD FRCPE FFPH	Professor of Epidemiology, Honorary Consultant in Public Health, Usher Institute, University of Edinburgh
---------------	---	---

⁷ End of appointment 14/07/2024

Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Vice Chair	Dr Majella Lane BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Lay Member	Mrs Ruth Paulin BPharm MRPharmS	
Member	Professor Hannah Batchelor BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde

Member	Dr Federico Brucoli Pharm. D. PhD CChem MRSC mGPhC FHEA	Senior Lecturer in Medicinal Chemistry, Leicester School of Pharmacy, De Montfort University, Leicester
Member	Professor Barbara R Conway BSc (Pharm) PhD FRPharmS CMgr FCMI	Head of Pharmacy and Professor of Pharmaceutics, University of Huddersfield, Huddersfield
Member	Professor Ben Forbes BPharm PhD	Professor of Pharmaceutics, Institute of Pharmaceutical Science, Kings College London
Member	Professor Nikoletta Fotaki MSc, PhD, FAAPS	Professor of Biopharmaceutics, Department of Life Sciences, Centre for Therapeutic Innovation (CTI), University of Bath
Member	Mr Robert Lowe BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Member	Professor Luigi (Gino) Martini BSc (Hons), PhD, MBA, FRPharmS, FRSC	Chief Executive Precision Health Technology Accelerator (PHTA), University of Birmingham Honorary

		Professor in Pharmacy, University of Birmingham
Member	Professor Afzal R Mohammed BPharm PhD	Professor of Pharmaceutics, Aston Pharmacy School, Aston University
Member	Professor Darragh Murnane PhD BSc (Pharm) PhD MRPharmS	Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire
Member	Professor Susannah E Walsh PhD BSc MBA	Head of School, Professor of Pharmaceutical Microbiology, Pharmacy and Life Sciences, Robert Gordon University
Member	Mr Hadar Zaman MPharm, MFRPSII, IPresc, FHEA	Chief Pharmacist, North Cumbria Integrated Care NHS Foundation Trust

Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Marc Turner MB ChB PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service
Lay Member	Dr Kirstie Shearman LLB MA PhD	Policy Manager, Health Research Authority
Member	Professor Farzin Farzaneh DPhil FRCPATH FRSB	Professor of Molecular Medicine, King's College London. Honorary Consultant in Specialist Medicine, King's College Hospital NHS Trust
Member	Professor Chris Goldring BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.

Member	Professor Andrew Pollard ⁸ PhD FRCPCH FMedSci	Chair of the Joint Committee on Vaccination and Immunisation; Professor of Paediatric Infection and Immunity, University of Oxford
Member	Dr Robin Thorpe PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Member	Professor Christina Yap MSci PhD Cstat	Professor of Clinical Trials Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research

⁸ End of appointment 16/07/2024

Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)

Post	Name and title	Affiliations
Chair	Professor Anthony Williams BSc MSc MRCP FRCPATH PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	Mr James Pitayanukul ⁹ BSc (Hons) MSc CA	
Member	Professor Michael Ardern-Jones BSc MBBS DPhil FRCP	Associate Professor, University of Southampton and Consultant Dermatologist
Member	Professor Anjan Dhar DM, MD (Medicine), FRCPE, AGAF, Cert. Med. Ed, FHEA	Professor of Medicine (Teesside University), Consultant Gastroenterologist, Clinical Lead for UGI

⁹ Appointed 22/03/2024

		Cancers, County Durham & Darlington NHS Foundation Trust
Member	Dr Shahida Din BMSc, MBChB, PhD, FRCP (Edin)	Consultant Gastroenterologist & NHS Research Scotland Clinician, NHS Lothian; Honorary Senior Clinical Lecturer, University of Edinburgh
Member	Professor Celia Moss OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPCH	Honorary Consultant Dermatologist, Birmingham Women's and Children's NHS FT; Honorary Professor of Paediatric Dermatology, University of Birmingham
Member	Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh
Member	Dr Ravishankar Sargur MD, FRCPPath, FRCP, MBA	Consultant Clinical Immunologist and Clinical Lead for Laboratory Immunology, Northern General Hospital, Sheffield

Member	Professor Nidhi Sofat PhD MBBS FRCP PGCert FHEA	Professor of Rheumatology, City St Georges University London and St George's University Hospitals NHS Foundation Trust
---------------	---	--

Membership of the Infection Expert Advisory Group (IEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Lay Member	Mrs Stella O'Brien MA (Hons)	
Member	Professor Brian Angus BSc MBChB MA (Oxon) MD (Glas) DTM&H FRCP FFTM (Glas)	Reader in Infectious Diseases and Professor of Practice, Medical Education, Chair of the UK Malaria Expert Advisory Group (UKMEAG)
Member	Dr Michael Brown BA BM BCh FRCP PhD DTM&H	Consultant Physician, Infectious Diseases & Acute Medicine, & Clinical Director, Division of Infection, University College London Hospitals NHS Foundation Trust & Honorary Associate Professor, Clinical Research Sept,

		London School of Hygiene & Tropical Medicine
Member	Professor Geraint Rhys Davies BM DTM&H PhD FRCP	Professor of Infection Pharmacology, University of Liverpool, Honorary Consultant in Infectious Diseases, Liverpool University Hospitals Foundation Trust
Member	Dr Andrew Freedman M.A, M.B, B. Chir, M.D, FRCP (Lond.), FRCP (Edin.)	Reader in Infectious Diseases, Cardiff University School of Medicine/ Hon. Consultant Physician, University Hospital of Wales
Member	Professor Richard J C Gilson MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health
Member	Dr Louis Grandjean MBBS BSc MSc PhD MRCPCH	Associate Professor Paediatric Infectious Diseases Great Ormond Street Hospital and University College London

Member	Dr Lim S Jones MBBCh, PhD, FRCPath.	Consultant Microbiologist, Public Health Wales Microbiology, Cardiff; Clinical Lead Specialist Antimicrobial Chemotherapy Unit, Cardiff; Chair of the All Wales Medical Microbiology Development & Standardisation Group
Member	Dr Matthias Schmid ¹⁰ MD FRCP DTMH	Consultant Physician, Head of Department of Infection & Tropical Medicine, Directive of Elective Studies Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne

¹⁰ Reappointed 09/09/2024

Membership of the Medicines for Women’s Health Expert Advisory Group (MWHEAG)

Post	Name and title	Affiliations
Chair	Professor Philip Hannaford ¹¹ MChB MD FRCGP FFPH FFSRH FRSE	Emeritus Professor of Primary Care, University of Aberdeen
Vice Chair	Dr Diana Wellesley FRCP	Honorary Consultant and Honorary Senior Lecturer in Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital Southampton
Lay Member	Dr Caitlin Dean RGN MSc PhD	Chair Trustee, Pregnancy Sickness Support
Lay Member	Ms Linda Pepper BA MA (Education)	Independent Consultant: patient and public involvement in healthcare

¹¹ Reappointed 11/04/2024

Member	Dr Kenneth Hodson MD MBCbB MRCP(UK) MRCOG	Head of UK Teratology Information Service UK Teratology Information Service
Member	Dr Sylvia Kama-Kieghe¹² FRCGP FRSM FRSPH DFSRH	Consultant in General Practice and Urgent Care, Sheffield GP Out of Hours. GP Tutor and Examiner, University of Sheffield. Digital Health Educator and Clinical Lead, Alevyn Ltd.
Member	Dr Asha Kasliwal FRCOG FFRSH FRCGP (Hon) FFPH (Hon)	Consultant in Community Gynaecology and Reproductive Health, Manchester University NHS Foundation Trust Hathersage Centre
Member	Dr Jonathan Lord MD FRCOG FHEA	Consultant obstetrician and gynaecologist, Royal Cornwall Hospitals NHS Trust

¹² Appointed 24/04/2024

Member	Dr Lucy MacKillop ¹³ BM BCh MA(Oxon.) FRCP FRCOG Ad Eundem	Consultant Obstetric Physician and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust, Oxford
Member	Professor Laura A Magee ¹⁴ MD (Hons) MSc FRCPC CertClinPharm FACP FRCOG	Professor of Women's Health, King's College London
Member	Dr Louise Massey MBChB FFSRH FFPH	Consultant in Sexual and Reproductive Health Aneurin Bevan University Health Board
Member	Dr Julia Prague MBBS PhD MRCP(UK) BSc	Consultant in Endocrinology, Diabetes, and General Internal Medicine, Royal Devon and Exeter NHS Foundation Trust, and Honorary Senior Clinical Lecturer, College of

¹³ Stepped down 08/05/2024

¹⁴ Appointed 24/04/2024

		Medicine and Health, University of Exeter
Member	Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
Member	Professor Laurie Tomlinson MBBS MSc PhD	NIHR research Professor, Faculty of Epidemiology and Population Health London School of Hygiene & Tropical Medicine

Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)

Post	Name and title	Affiliations
Chair	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Dr Lisa Brownell BSc(Hons) MBChB PGCertMedEd FHEA FRCPsych	Associate Medical Director, Birmingham and Solihull Mental Health NHS Foundation Trust Chair of Area Prescribing Committee, Birmingham, Sandwell, Solihull and Environs
Member	Professor Naomi Fineberg BA Hons MB BS MA MRCPsych	Consultant in General Psychiatry, Hertfordshire Partnership University NHS Foundation Trust
Member	Dr Barry Mark Miller MB ChB FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Bolton NHS Foundation Trust.

		Board Member of the Faculty of Pain Medicine
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Dr Waqar Rashid MBBS BSc MRCP(UK) PhD	Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, member of the Multiple Sclerosis Society
Member	Dr Fergus Rugg-Gunn ¹⁵ MB BS MRCP PhD	Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square London
Member	Dr Aditya Sharma MBBS MD MRCPsych PhD	Clinical Senior Lecturer and Honorary Consultant in Child and Adolescent Psychiatry at Newcastle University and Cumbria, Northumberland Tyne and Wear NHS Foundation Trust

¹⁵ Reappointed 21/01/2024

Member	Dr Hoo Kee Tsang BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees
---------------	---	--

Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)

Post	Name and title	Affiliations
Chair	Professor Poulam M Patel ¹⁶ PhD MBBS FRCP	Professor of Clinical Oncology, University of Nottingham
Vice Chair	Professor James Spicer FRCP PhD	Professor of Experimental Cancer Medicine, King's College London, Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	Professor Janet E Brown FRCP MD MSc BMedSci MBBS	Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield

¹⁶ Reappointed 06/07/2024

Member	Dr Perminder Tony Singh Dhillon ¹⁷ Bsc, MB BS, FRCP, PhD	Consultant Medical Oncologist, Royal Surrey Hospital, Guildford, Surrey and Hon. Senior Lecturer in Oncology, University of Surrey
Member	Dr Anjum Khan PhD MBChB FRCPATH MRCP	Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
Member	Dr Rebecca Kristeleit BSc MBChB PhD FRCP FRSB	Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
Member	Professor Siow Ming Lee PhD FRCP	Professor of Medical Oncology, Consultant Medical Oncologist, University College London Hospital
Member	Dr Debashis Sarker ¹⁸ MBChB PhD FRCP	Reader in Experimental Oncology, King's College London Consultant Medical Oncologist, Guy's, St Thomas' and King's College Hospitals

¹⁷ Appointed 01/04/2024

¹⁸ Appointed 01/04/2024

Member	Dr Ben Uttenthal MA MB BS PhD MRCP FRCPath	Consultant Haematologist, Cambridge University Hospitals
---------------	--	---

Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)

Post	Name and title	Affiliations
Chair	Professor Steven Cunningham MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Vice Chair	Dr Kathryn Johnson MBChB FRCPCH	Consultant Neonatologist & Research Lead Yorkshire & Humber CRN Children's Specialty Lead Clinical Lead, National Congenital Anomaly and Rare Disease Registration Service, NHSD, Leeds General Infirmary

Lay Member	Dr Jacqueline McMurtrie ¹⁹ BSc (Hons) MSc PhD	
Lay Member	Mrs Rhian Thomas-Turner ²⁰ LLM PG Dip Legal Practice	Research and Development Lead, Noah's Ark Children's Hospital for Wales, Cardiff and Vale University Health Board
Member	Mrs Catrin Barker	Pharmacist, NHS Professionals
Member	Dr Simon B Drysdale ²¹ BSc (Hons) MBBS PgDipPID PhD FRCPCH FHEA	Consultant in Paediatric Infectious Diseases and Immunology, St George's University Hospital NHS Foundation Trust Honorary Senior Lecturer, St George's, University of London
Member	Dr Martin William English BMSc MBChB	Consultant Paediatric Oncologist, Birmingham Women's and Children's Hospital NHS Foundation Trust

¹⁹ Reappointed 28/01/2024

²⁰ Reappointed 28/01/2024

²¹ Reappointed 26/09/2024

	MD, FRCP(Glas), FRCPCH	
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Member	Dr Caroline Jones MB ChB FRCPCH MD	Consultant Paediatric Nephrologist, Alder Hey Children's Hospital NHS Foundation Trust
Member	Dr Ashley Liew MBChB MRCPsych MSc	Consultant Paediatric Neuropsychiatrist, Evelina London Children's Hospital and South London & Maudsley NHS Foundation Trust. Honorary Senior Research Fellow, University of Warwick
Member	Dr Daniel E Lumsden MB/BChir MA Cantab MSc PhD FRCPCH	Consultant Paediatric Neurologist, Evelina London Children's Hospital Adjunct Clinical Senior Lecturer, Department of Perinatal Imaging, King's College London

Member	Dr Rubin Minhas²² MB ChB MBA	GP Principal
Member	Dr Clare Pain BMBS MSc MRPCH	Consultant Paediatric Rheumatologist, Clinical Lead for Rheumatology Honorary Clinical Lecturer, University of Liverpool Co-Chair of NIHR CRN: children/Versus Arthritis Paediatric Rheumatology Clinical Studies Group Associate Director, UK Experimental Arthritis Treatment Centre for Children (Behcet's and scleroderma workstreams)
Member	Dr Guido Pieles PhD MD	Consultant Congenital Cardiologist Congenital Hear Unit, Bristol Heart Institute

²² End of Appointment 14/07/2024

Member	Professor Shirley Price MSc PhD FBTS FRSB ERT FHEA FRSC MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Mrs Julia Taylor MSc BSc	Paediatric Advanced Nurse Practitioner, High Dependency Unit, Alder Hey Children's NHS Foundation Trust.
Member	Dr William John Watkins BSc PhD	Senior Statistician/Lecturer, College of Biomedical & Life Sciences, Cardiff University

Membership of the Pharmacovigilance Expert Advisory Group (PEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Vice Chair	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD, MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Lay Member	Ms Susan Hunneyball BSc (Hons)	
Lay Member	Dr Malcolm Oswald ²³	Honorary Research Fellow in Law, University of Manchester

²³ Appointed 22/03/2024

Lay Member	Mrs Madeleine Wang²⁴	
Member	Mrs Alana Adams BPharm (Hons) MSc IP MRPharmS	Principal Pharmacist Medicines Information, advice and Safety, University of Cardiff
Member	Professor Darren Ashcroft BPharm MSc PhD FRPharmS	Professor of Pharmacoepidemiology, Head, Drug Usage and Pharmacy Practice Group, University of Manchester
Member	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	Professor Richard FitzGerald MD MBChB PhD FRC	CRF Director, NIHR Royal Liverpool and Broadgreen CRF
Member	Professor Patricia McGettigan BSc (Pharm)	Professor of Clinical Pharmacology and Medical Education, Queen Mary

²⁴ End of Appointment 21/01/2024

	MD FRCPI FRACP SFHEA FBPhS	University of London; Consultant Physician, Barts Health NHS Trust
Member	Dr Fraz Arif Mir MA FRCP	Consultant Physician, Cambridge University Hospitals NHS Foundation Trust
Member	Professor Rupert Payne MB ChB PhD MRCP FRCPE FBPhS FHEA	Professor of Primary Care & Clinical Pharmacology University of Exeter
Member	Dr Nashat Qamar ²⁵ MB ChB MRCP MSc DRCOG BSc (hons)	PCN Clinical Director and GP Partner, Hall Green Health, Birmingham.
Member	Professor Reecha Sofat MBBS, FRCP, PhD	Breckenridge Chair of Clinical Pharmacology and Therapeutics, University of Liverpool.
Member	Dr Anna Schultze ²⁶ BSc MSc PhD	Assistant Professor in Pharmacoepidemiology, Faculty of

²⁵ Appointed 22/03/2024

²⁶ Appointed 22/03/2024

Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)

Post	Name and title	Affiliations
Chair	Professor Angela Thomas OBE MB BS PhD FRCPE FRCPATH	University of Edinburgh
Lay Member	Ms Susan Hunneyball BSc (Hons)	Member of the Pharmacovigilance Expert Advisory Group (PEAG) and Advisory Board on the Registration of Homeopathic Products (ABRHP)
Lay Member	Ms Linda Pepper BA MA (Education)	Member of the Medicines for Women's Health Expert Advisory Group (MWHEAG) and the Isotretinoin Expert Working Group (IEWG)
Member	Professor Tony Avery OBE	GP and Professor of Primary Health Care, National Clinical Director for Prescribing (NHS England)

Member	Professor Arianna Di Florio MD PhD	Professor of Psychiatry, Cardiff University
Member	Professor Nicol Ferrier	Professor of Psychiatry, Institute of Neuroscience, Newcastle University
Member	Dr Jamie Fraser BSc (Hons) MBChB MRCPGP	GP Partner, Southside Surgery, Inverness
Member	Ellie Gordon	Royal College of Nursing
Member	Professor David Kessler MD MRCPGP MRCPsych MBBS BA	Professor of Primary Care, Bristol Medical School, University of Bristol
Member	Professor Glyn Lewis	Professor of Psychiatric Epidemiology, University College London
Member	Dr Barry Miller MB Ch.B FRCA FFPMRCA FCEM	Consultant, Pain Management and Anaesthetics, Bolton NHS Foundation Trust
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh

Member	Mr Peter Pratt	National Specialty Adviser for mental health pharmacy, NHS England
Member	Professor Vanessa Raymont MBChB MSc MRCPsych	Associate Professor, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust
Member	Dr Aditya Sharma	Consultant Child & Adolescent Psychiatrist/Clinical Lead, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
Member	Professor David Taylor FRPharmS FRCPE FRCPsych (Hon)	Director of Pharmacy and Pathology, King's College London
Member	Dr Hoo Kee Tsang BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees

Member	Dr Morris Zwi MBBCh FRCPsych	Honorary Consultant Psychiatrist, South West London & St George's NHS Mental Health Trust
---------------	--	---

Membership of the CHM's Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG)

Post	Name and title	Affiliations
Chair	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Lay Member	Mrs Julia Cons	
Member	Dr Robert Andrews SFHEA FHEA	Senior Lecturer Data Hub at Heath, Cardiff

Member	Dr Colin Brown PhD FRCPATH	Consultant Clinical Scientist -Head of H&I Laboratory Colindale NHS Blood and Transplant
Member	Professor Robert Brown BSc PhD	Emeritus Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	Dr Peter Buckle FRSPH, FIEHF, FIEA, C.ErgHF	Principal Research Fellow, NIHR London In Vitro Diagnostics Co-operative Department of Surgery and Cancer, Faculty of Medicine, Imperial College London
Member	Professor Tom Clutton- Brock MBE MB ChB FRCP FRCA FFICM	Director, Medical Devices Testing and Evaluation Centre, Clinical Director, NIHR HealthTech Research Centre in Devices, Digital and Robotics, Chair, NICE Interventional Procedures Advisory Committee, Associate Medical Director, University Hospitals Birmingham NHS Foundation Trust, Professor of

		Anaesthesia & Intensive Care Medicine, University of Birmingham, Chair of the interim Devices Committee
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Member	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	Professor Jon Deeks PhD CStat FMedSci	Professor of Biostatistics, Department of Applied Health Science, College of Medicine and Health, University of Birmingham
Member	Dr Brendan Fish BSc PhD	Director of Biologics & RNA Centre of Excellence
Member	Professor Eric Lim MB ChB MD MSc FRCS(C-Th)	Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic Surgery, Imperial College London

Member	Mr Robert Lowe BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Member	Dr David Millrine PhD	Translational Immunology Team lead, CRUK Cancer Biomarker Centre, University of Manchester
Member	Professor Christian Ottensmeier MD, PhD, FRCP	Professor of Molecular and Clinical Cancer Medicine, University of Liverpool
Member	Professor Poulam Patel PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie BSc PhD	Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences
Member	Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA

Member	Professor Jacqui Shaw BSc PhD	Group Leader and Professor of Translational Cancer Genetics, Leicester University
Member	Professor James Spicer FRCP, PhD	Professor of Experimental Cancer Medicine, King's College London; Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	Professor Nigel Stallard B MSc PhD	Professor of Medical Statistics Director Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry
Member	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Member	Dr Robin Thorpe BSc PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Member	Dr David Turner PhD FRCPATH	H&I Laboratory, Scottish National Blood Transfusion Service, Royal Infirmary of Edinburgh
Member	Professor Marc Turner MB ChB PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service
Member	Professor Christopher Weir BSc MSc PhD FRSS Cstat	Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM)
Member	Professor Anthony Williams BSc MSc MRCP, FRCPATH, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust

Member	Professor Christina Yap ²⁷ MSci PhD C. Stat	Professor of Clinical Trial Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research [Cancer UK/ UK CI]
Member	Professor Christopher Yao MA MEng DPhil	Professor of Artificial Intelligence, Nuffield Department of Women's & Reproductive Health, University of Oxford and Health Data Research UK
Member	Professor Ly-Mee Yu BSc MSc DPhil	Professor of Clinical Trials and Biostatistics, Deputy Director Academic of Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford

²⁷ Stepped down 10/09/2024

Membership the Real World Data Expert Working Group (RWD EWG)

Post	Name and title	Affiliations
Chair	Professor Deborah Ashby OBE FMedSci	Interim Dean of the Faculty of Medicine, Imperial College London
Member	Professor Janet Darbyshire CBE MB ChB FMedSci FRCP FFPH FRSS (Hon)	Emeritus Professor of Epidemiology, University College London
Member	Dr J Colin Forfar BSc(Hons) MA(Oxon) MD PhD FRCP FRCPE	Retired Consultant Physician and Cardiologist, John Radcliffe Hospital, Oxford
Member	Professor Peter Hall MB ChB MRCP PhD	Professor and Honorary Consultant in Medical Oncology
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Member of Pharmacovigilance Expert Advisory Group

		(PEAG) and Member of Paediatric Medicines Expert Advisory Group (PMEAG)
Member	Professor Sarah Meredith	Professor of Clinical Trials, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, Invited Expert of the Commission on Human Medicines (CHM)
Member	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science, Chair of the Commission on Human Medicines (CHM)
Member	Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh

Membership of the Valproate Epigenetics Expert Working Group (VEEWG)

Post	Name and title	Affiliations
Chair	Professor Anthony Williams BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	Ms Julia Cons	
Member	Professor Robert Brown BSc PhD	Emeritus Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	Professor Amanda Drake	Retired, Professor, Centre for Cardiovascular Science The Queen's Medical Research Institute University of Edinburgh

Member	Professor Timothy Gant	Head of the Toxicology Department, Radiation Effects Department Radiation, Chemical & Environmental Hazards
Member	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor Rod Mitchell	Professor of Developmental Endocrinology, Centre for Reproductive Health, University of Edinburgh Honorary Consultant Paediatric Endocrinologist, Royal Hospital for Children and Young People, Edinburgh
Member	Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Professor Heather M Wallace PhD FRCPATH	Professor Emeritus of Biochemical Pharmacology and Toxicology, University of Aberdeen

	FRSC FRSB FBTS FBPhS ERT	
Member	Member1	Professor at the Human Genetics Unit
Member	Member2	Professor of Developmental Epigenetics. MRC Laboratory of Medical Sciences and Imperial College London, Faculty of Medicine

membership of the CHM's Valproate Implementation Working Group (VIEWG)

Post	Name and title	Affiliations
Chair	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor Helen Cross	The Prince of Wales's Chair of Childhood Epilepsy, Director UCL Great Ormond Street Institute of Child Health
Member	Professor Naomi Fineberg	Consultant Adult Psychiatrist and Professor of Psychiatry, University of Hertfordshire
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Reader Paediatric Clinical Pharmacology Women's & Children's Health, University of Liverpool. Consultant Paediatric Clinical Pharmacologist (Alder Hey Children's Hospital). Director of Research Alder Hey Children's Hospital and Director of NIHR Alder Hey Clinical Research Facility (CRF)

Member	Mr Tony Jamieson FRPharmS	Patient Safety Specialist & Clinical Improvement Lead. Medicines Safety Improvement Programme, NHS England
Member	Professor Anthony Marson	Professor of Neurology, University of Liverpool, The Walton Centre NHS Foundation Trust, NIHR Senior Investigator
Member	Dr Tejal Mitchell	Consultant Neurologist Subspecialty Lead for Epilepsy, Northwest Anglia NHS Foundation Trust and Cambridge University Hospitals NHS Foundation Trust
Member	Ms Kim Morley²⁸	Advanced Clinical Nurse/Midwife Practitioner in Epilepsy, Hampshire Hospitals NHS Foundation

²⁸ Retired in 2024

Member	Prof Finbar O'Callaghan	Professor of Paediatric Neuroscience, Developmental Neurosciences Dept UCL GOS Institute of Child Health
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Dr Vanessa Raymont	Senior Clinical Researcher and Honorary Consultant Psychiatrist, Department of Psychiatry, University of Oxford
Member	Dr Martin Wilson	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness
Member	Member3	Consultant Neurologist
Member	Member4	Consultant Neurologist
Member	Member5	Regional Chief Pharmacist, East of England / National CDAO Lead, Medical Directorate, NHS England
Member	Member6	Specialist in Child and Adolescent psychopharmacology CAMHS Medical Director

ANNEX A - DECLARATION OF INTERESTS

Commission on Human Medicines, Commission’s Expert Advisory Groups, Expert Working Groups and ad hoc groups members have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Member	Committee(s)	Interest Type	Company / Organisation / Sponsor	Nature of Interest	Current	Additional Information
Aditya Sharma	NPPEAG , ARMEWG	Personal	NIL	N/A	N/A	

Aditya Sharma	NPPEAG , ARMEW G	Non- Perso nal	Lundbeck	Unrestricted medical educational grant towards a study	No
Afzal Moham med	CPSEAG	Perso nal	Aston Particle Technolo gies	Shares, Consultancy	Yes
Afzal Moham med	CPSEAG	Non- Person al	Catalent Pharma	Research Grant	Yes
Afzal Moham med	CPSEAG	Non- Person al	Colorcon Ltd	Research Grant	No

Afzal Mohammed	CPSEAG	Non- Person al	MaxBiotech Ltd	Research Grant	Yes
Afzal Mohammed	CPSEAG	Non- Person al	Proveca Ltd	Research Grant	Yes
Afzal Mohammed	CPSEAG	Non- Person al	Eye Docs Ltd	Research Grant	Yes
Afzal Mohammed	CPSEAG	Non- Person al	Quest Healthcare	Research Grant	Yes
Alana Adams	PEAG	Person al	NIL	N/A	N/A

Alana Adams	PEAG	Non-Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Conferences/Scientific Meetings	Lilly	I have declined all honorarium related to this, including indirectly (i.e. to my employing institution). I receive travel	No	I am an academic participant on the steering committee of this trial ('TRIUMPH') for

support when
meeting are face-
to-face.
methodology – no
financial personal
gain. No products
discussed.

an unlicensed
compound.

Amanda Adler CHM,
CDRRA
EAG Additional

I do not accept
income from the
device or
pharmaceutical
industry. I work
for Oxford
University,
which does
receive support
from the

pharmaceutical industry.

Amanda Drake	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Amanda Drake	Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A
Amine Boualem	CDRRA EAG	Personal	NIL	N/A	N/A
Amine Boualem	CDRRA EAG	Non-Personal	NIL	N/A	N/A

Andrew Freedman	IEAG	Person	NIL	N/A	
Andrew Freedman	IEAG	Non-Personal	Moderna	One PA of my salary is paid by Health & Care Research Wales to act as Clinical Lead for Infection Vaccine Trials in Wales. This session is reimbursed by Moderna (although my role is not limited to Moderna trials).	Yes

Andrew Pollard	CTBVEAG	Personal	Shionogi	Consultancy	No	Interest held for 1 day
Andrew Pollard	CTBVEAG	Personal	AstraZeneca	AJP is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca	No	
Andrew Pollard	CTBVEAG	Non-Personal	AstraZeneca, GSK, Sanofi	Unrestricted grant for 3 day educational course paid to Oxford University	No	

Andrew Pollard	CTBVEAG	Non-Personal	AstraZeneca	Research grant to support clinical trials on the COVID19 vaccine	No
Andrew Pollard	CTBVEAG	Non-Personal	Moderna	Supply of materials by Moderna for use in UK Gov funded research	Yes
Andrew Pollard	CTBVEAG	Non-Personal	Serum Institute of India	Grant to conduct laboratory studies and clinical trials	Yes
Andrew Pollard	CTBVEAG	Non-Personal	DHSC	Chair of JCVI	Yes

Andrew Pollard	CTBVEA G	Non- Person al	WHO	Chair of WHO technical advisory group on Salmonella vaccines	Yes
----------------	-------------	----------------------	-----	--	-----

Andrew Pollard	CTBVEA G	Additio nal			Non-commercial Grants from Wellcome and Bill & Melinda Gates Foundation on typhoid and paratyphoid vaccines, Medical Research Council (MRC)
----------------	-------------	----------------	--	--	--

on paratyphoid vaccine (with University of Maryland; current); Grant from the Gavi on pneumococcal vaccines in Nepal (2013-2024).

Andrew Pollard CTBVEA G Additional

European Commission (EC): Preparing for RSV Immunisation and Surveillance in Europe

Andrew Pollard CTBVEA G Additional

(PROMISE) on RSV biomarkers (Current).
Horizon 2020 grant
(DIAMONDS) on fever in children and pneumonia (current); EC grant (Innovac4) to develop a Clostridioides difficile challenge model (current);

Grants from Innovate UK to

develop plague,
Q fever vaccines
(current) and
Chikungunya/M
ayaro Virus
vaccines
(current).

Andrew
Pollard CTBVEA Additio
 G nal

Grants from
Coalition for
Epidemic
Preparedness
Innovations
(CEPI) on
COVID19
vaccines (2021-
2024)

Andrew Pollard CTBVEA G Additional

A grant was received by Oxford University from National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) for work on their COVID-19 vaccine (2020 – 2024)

Andrew Pollard CTBVEA G Additional

Oxford University has made a strategic

partnership with
Coalition for
Epidemic
Preparedness
Innovations
(CEPI) in 2023
for the
development of
vaccines against
future outbreaks
and pandemics,
a role in co-
ordination
however is not
receiving any
research funding

under this agreement.

Andrew Pollard CTBVEA G Additional

Chair of DHSC's Joint Committee on Vaccination and Immunisation (Unpaid)

Andrew Pollard CTBVEA G Additional

Member of WHO's SAGE until 2022 (Unpaid)

Andrew Pollard CTBVEA G Additional

Chair of WHO's Salmonella TAG until end of 2024 (Unpaid)

Andrew Pollard	CTBVEAG	Additional				Grant from Bill & Melinda Gates Foundation on evaluating infant schedules (current)
Andrew Rice	NPPEAG	Personal	AstraZeneca, Combi gene	Consultancy	Yes	
Andrew Rice	NPPEAG	Personal	Imperial College	Employee	Yes	
Andrew Rice	NPPEAG	Non-Personal	NIL	N/A		

Andrew NPPEAG Additio
Rice nal

ASCR is named as an inventor on patents (neither being actively pursued at present) :

- Rice A.S.C., Vandevorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771
- Okuse K. et al Methods of

treating pain by inhibition of VGF activity
EP13702262.0/
WO2013 110945

Andrew Rice NPPEAG Additional

Member Joint Committee on Vaccine and Immunisation-varicella sub-committee – until 15.1.24

Andrew Rice NPPEAG Additional

Member of Non Freezing Cold Injury Independent

Andrew Rice NPPEAG Additional

Senior Advisory Committee

Member of Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks (ACTTION) steering committee (until 2024)

Andrew Rice NPPEAG Additional

Grants and studentships - UKRI (Medical Research

Council &
BBSRC), Versus
Arthritis, Alan
and Sheila
Diamond Trust,
Royal British
Legion,
European
Commission,
Ministry of
Defence, Dr
Jennie Gwynn
Bequests, The
British Pain
Society, Royal
Society of
Medicine

Andrew
Rice

NPPEAG

Additional

Honoraria 2024:
Hospital for
Special Surgery
– New York –
speakers
honorarium
United Arab
Emirates
University –
reviewers
honorarium

Andrew
Rice

NPPEAG

Additional

International
Association
Study of Pain:
Executive
Committee
(President-elect.

Became President August 2024). In context of IASP duties - travel and related expenses. Speakers honoraria donated to IASP

Angela Thomas	ARMEWG	Personal	Moderna	Expenses Paid	Yes
Angela Thomas	ARMEWG	Non-Personal	NIL	N/A	N/A

Anita Simonds	CDRRA EAG	Personal	Biogen/A CI Clinical	Member of Endpoint Adjudication Committee for BioALS RCT of this drug for motor neurone disease patients with SOD-1 mutation. (no financial interest in drug or trial -my role is to review endpoint events).	No
Anita Simonds	CDRRA EAG	Non-Personal	NIL	N/A	No

Anjan Dhar	GRIDEA G	Person al	Takeda UK	Consultancy and advisory role, speaker fees	No
Anjan Dhar	GRIDEA G	Person al	Janssen UK	Consultancy, advisory and speaker fees	No
Anjan Dhar	GRIDEA G	Person al	Dr Falk Pharma UK	Consultancy, advisory and speaker fees	No
Anjan Dhar	GRIDEA G	Person al	Galapagos	Advisory role, speaker fees	No
Anjan Dhar	GRIDEA G	Person al	Abbvie UK	Speaker fees and Chair	No
Anjan Dhar	GRIDEA G	Person al	BMS	Speaker fees	No

Anjan Dhar	GRIDEA G	Personal	Health Beacon	Speaker fees	No
Anjan Dhar	GRIDEA G	Personal	Tillotts UK	Speaker fees and Chair	No
Anjan Dhar	GRIDEA G	Personal	Pharmacosmos	Speaker fees and hospitality	No
Anjan Dhar	GRIDEA G	Conferences/Scientific Meetings	Abbvie	ECCO 2024: Full registration, travel and accommodation	No
Anjan Dhar	GRIDEA G	Conferences/Scientific	Johnson and Johnson	United European Gastroenterology Week: Full registration, travel	No

Meetings and accommodation

Anjan Dhar	GRIDEAG	Non-Personal	NIL	N/A	
Anjum Khan	OHEAG	Personal	Astellas	Fee-paid work	No
Anjum Khan	OHEAG	Personal	Jazz	Fee-paid work	No
Anjum Khan	OHEAG	Personal	AbbVie	Fee-paid work	No
Anjum Khan	OHEAG	Personal	Immedica	Consultancy	No

Anjum Khan	OHEAG	Personal	Incyte	Consultancy	No
Anjum Khan	OHEAG	Personal	Servier	Fee-paid work	No
Anjum Khan	OHEAG	Personal	TCBioPharm	Fee-paid work	No
Anjum Khan	OHEAG	Personal	Synaigen	Consultancy	No
Anjum Khan	OHEAG	Conferences/Scientific Meetings	Jazz	Conference registration, Train Ticket & accommodation	No

Anjum Khan	OHEAG	Non-Personal	Nil	N/A	N/A
Ann Daly	PEAG, HPM EWG	Personal	NIL	N/A	N/A
Ann Daly	PEAG, HPM EWG	Non-Personal	NIL	N/A	N/A
Anna Schultze	PEAG	Personal	NIL	N/A	
Anna Schultze	PEAG	Non-Personal	GSK	A grant for research, as well the studentship of	Yes

two of my PhD students.

Anthony Avery	ARMEWG	Personal	NIL	N/A
Anthony Avery	ARMEWG	Non-Personal	NIL	N/A
Anthony Avery	ARMEWG	Additional		

National Clinical Director for Prescribing for NHS England with clinical responsibility for promoting initiatives to address the

overprescribing
of medicines.
This includes
potential
overprescribing
of
antidepressants,
and I have
worked on a
number of
initiatives relating
to this including:
1) Advising
organisations
responsible for
providing
educational
materials for

clinicians to
update guidance
on the
appropriate
prescription of
antidepressants,
and how best to
help patients
withdraw from
antidepressants
(should they wish
to do so); 2)
Promoting the
appropriate use
(and withdrawal)
of
antidepressants
in conference

presentations
and at
educational
events, as well
as promoting
NICE-endorsed
alternatives to
antidepressant
(where
appropriate); 3)
Promoting the
2023 NHS
England
document:
Optimising
personalised
care for adults
prescribed

medicines
associated with
dependence or
withdrawal
symptoms:
Framework for
action for
integrated care
boards (ICBs)
and primary care;
4) Working with
the 'Beyond Pills'
All Party
Parliamentary
Group to
highlight
problems
associated with

overuse of
antidepressants
and problems
with
antidepressant
withdrawal; 5)
Working with the
Specialist
Pharmacy
Service to
develop materials
to help clinicians
better support
patients who
choose to
withdraw from
antidepressants.

Anthony ARMEW Additio
Avery G nal

A clinical
academic at the
University of
Nottingham. Via
the University of
Nottingham I
have received
(and continue to
receive) external
non-commercial
funding to
undertake
research on the
frequency,
nature and
causes of
medication
safety problems

(mainly in primary care) and interventions aimed at improving medication safety (mainly in primary care).

NIHR Senior Investigator.

Practising GP, currently working as a part-salaried GP.

Anthony ARMEW Additio
Avery G nal

Anthony ARMEW Additio
Avery G nal

Anthony Williams	PEAG	Personal	NIL	N/A	N/A
Anthony Williams	PEAG	Non-Personal	NIL	N/A	N/A
Anthony Marson	VIEWWG	Personal	NIL	N/A	N/A
Anthony Marson	VIEWWG	Non-Personal	GSK and Sanofi	Honoraria for providing lectures paid to University of Liverpool.	No
Anthony Marson	VIEWWG	Non-Personal	UCB Pharma	Research grant paid to University of Liverpool	No

Anthony Marson	VIEWWG	Non- Personal	Jazz	Fees paid to University of Liverpool for lecture	No
Arianna Di Florio	ARMEWG	Personal	NIL	N/A	N/A
Arianna Di Florio	ARMEWG	Non- Personal	NIL	N/A	N/A
Asha Kasliwal	MWHEAG	Personal	Theramex	Lecture fees and travel expenses received for talk on Women's Health Hubs	No

Asha Kasliwal	MWHEAG	Non-Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Non-Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Additional			I do not expect any of the following to

impact my
partiality but
include it as per
the Code:

- I am a Council Member of the British Paediatric Neurology Association, a charity which represents Paediatric Neurologists in the UK)
- I am an Executive Committee member of the

Child and
Adolescent
Faculty of the
Royal College of
Psychiatrists
• I am Co-Chair
of the Scientific
Advisory
Committee for
the Smith-
Magenis
Syndrome
Foundation, a
charity which
supports families
with a member
who has this

genetic
syndrome

Barbara Conway	PEAG	Person al	NIL	N/A	N/A
Barbara Conway	PEAG	Confer ences/ Scienti fic Meetin gs	Journal of Woundcar e	Wounds Week: Honorarium	No
Barbara Conway	PEAG	Non- Person al	NIL	N/A	N/A
Barry Miller	NPP EAG,	Person al	NIL	N/A	N/A

	ARMEWG					
Barry Miller	NPP EAG, ARMEWG	Non-Personal	NIL		N/A	N/A
Barry Miller	NPP EAG, ARMEWG	Additional				Elected Board Member of the Faculty of Pain Medicine (FPM) (and former Dean) Current Lead for Medicines Management at the FPM, with specific remit

covering the
'Opioids Aware'
website a
national
resource for
guidance on
opioid
prescribing

Ben Forbes	CPSEAG	Personal	NIL	N/A	N/A
Ben Forbes	CPSEAG	Non-Personal	NIL	N/A	N/A
Ben Uttenthal	OHEAG	Personal	Gilead (Kite)	Sponsorship for conference attendance,	Yes

				speaker fees, honoraria for advisory board	
Ben Uttenthal	OHEAG	Person al	Sartorius	Consultancy for product development; potential support for academic programme that I direct	Yes
Ben Uttenthal	OHEAG	Person al	Swarm Oncology	Consultancy	Yes
Ben Uttenthal	OHEAG	Person al	Analog Devices	Consultancy	No

Ben Uttenthal	OHEAG	Person Kyverna al	Sponsorship for conference attendance, honorarium for advisory board	No
Ben Uttenthal	OHEAG	Person Abbvie al	Sponsorship for conference attendance; speaker fees	Yes
Ben Uttenthal	OHEAG	Person Autolus al	Sponsorship of clinical trial of which I am principal investigator	Yes
Ben Uttenthal	OHEAG	Confer American ences/ Society of	Sponsorship of travel / registration	No

		Scientific Meetings	Haematology annual meeting	fees and provision of accommodation	
Ben Uttenthal	OHEAG	Conferences/Scientific Meetings	International Conference on Malignant Lymphoma (ICML)	Sponsorship of travel/registration fees and provision of accommodation	No
Ben Uttenthal	OHEAG	Conferences/Scientific	Summit on Cell Therapy in Autoimmu	Sponsorship of travel/registration fees and provision of accommodation	No

Meetings
Disease

Ben
Uttenthal

OHEAG

Non-
Personal

Autolus

Sponsorship of
clinical trial of
which I am
principal
investigator

Yes

Brendan
Fish

HPM
EWG

Personal

GSK,
Haleon

Shares

Yes

Brendan
Fish

HPM
EWG

Non-
Personal

NIL

N/A

N/A

Brendan
Fish

HPM
EWG

Additional

I work for the
Centre for
Process
Innovation, an

innovation social
enterprise part
of the UK
Governments
High Value
Manufacturing
Catapult. CPI
helps pharma
companies to
scale up new
medicines,
develop vaccine
production
capacity, and
navigate the
complex
regulatory
pathways

needed to get to market.

My teams work on the unique challenges in designing, developing, and scaling biologic drugs

(everything from recombinant proteins to antibodies, VLPs and gene therapies).

At our RNA Centre of Excellence (a UK-based open-

access facility)
we work with a
variety of
academics,
SME's, and the
Pharmaceutical
Industry on RNA
manufacturing
solutions and
scaling up RNA
therapeutics
ready to use in
clinical trials.
CPI's offer is
unique because
we're agnostic
to who we work
with and we
care about

innovation, not profit. We want to develop ground-breaking new products, but they aren't ours to market. We exist purely to help others. If we discover an exciting new way of manufacturing RNA, for example, we will let anyone use it

in their own processes.

Brian Angus	IEAG	Personal	NIL	N/A	N/A
Brian Angus	IEAG	Non-Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Non-Personal	NIL	N/A	N/A
Member 6	VIEWG	Personal	NIL	N/A	N/A

Member 6	VIEWWG	Non- Person al	NIL	N/A	N/A
Caroline Jones	PMEAG	Person al	NIL	N/A	N/A
Caroline Jones	PMEAG	Non- Person al	Travere Therapeut ics	Co-Investigator on research trial at Alder Hey Children's Hospital	No
Caroline Jones	PMEAG	Non- Person al	Astellis	PI on research trial at AHCH	No
Catrin Barker	PMEAG	Person al	NIL	N/A	N/A

Catrin Barker	PMEAG	Non- Personal	NIL	N/A	N/A
Celia Moss	GRIDEA G	Personal	NIL	N/A	N/A
Celia Moss	GRIDEA G	Non- Personal	NIL	N/A	N/A
Celia Moss	GRIDEA G	Additional			Trustee of National Eczema Society Member of British Association of Dermatologists

Chris Goldring	CTBVEA G	Personal	NIL	N/A	N/A
Chris Goldring	CTBVEA G	Non-Personal	Pfizer, MSD, Roche, Eli Lilly, Novartis, Janssen, Sanofi-Aventis	Grant on Innovative Medicines Initiative Project	Yes
Chris Goldring	CTBVEA G	Non-Personal	RedX Pharma	Consultancy paid into University of Liverpool research account	Yes

Chris Goldring	CTBVEA G	Non- Person al	Merck	Grant. Completion of research papers associated with this work.	No
Chris Goldring	CTBVEA G	Non- Person al	Eli Lilly, Abbvie, Servier, Sanofi- Aventis, AZ, GSK, Janssen, Orion, B.I.	Grant. Completion of research papers associated with this work.	No
Christian Ottensmeier	HPMEW G	Person al	Neuvogen	Consultancy	Yes

Christian Ottensm eier	HPMEW G	Person al	Transgen e	Consultancy	Yes
Christian Ottensm eier	HPMEW G	Non- Person al	Transgen e	CI of clinical trial	Yes
Christian Ottensm eier	HPMEW G	Non- Person al	Scancell	CI of clinical trial	Yes
Christian Ottensm eier	HPMEW G	Non- Person al	BioNtech	CI of clinical trial	Yes
Christian Ottensm eier	HPMEW G	Non- Person al	Akamis bio	CI of clinical trial	Yes

Christian Ottensmeyer	HPMEWG	Non-Personal	Bristol Myers Squibb	Research funding	
Christian Ottensmeyer	HPMEWG	Non-Personal	Touchlight Genetics	Discussions of trial development / grant	Yes
Christian Ottensmeyer	HPMEWG	Non-Personal	Merck	Clinical trials funding, PI role and TMG role	Yes
Christian Ottensmeyer	HPMEWG	Non-Personal	Verastem	Clinical trials funding, , PI role and TMG role	Yes
Christian Ottensmeyer	HPMEWG	Non-Personal	Lineage therapeutics	Trial funding to Southampton University hospitals (trial	Yes

				sponsored by (CRUK)	
Christina Yap	CTBVEA G, HPMEW G	Person al	Faron Pharmace uticals	Independent Statistical Consultant	No
Christina Yap	CTBVEA G, HPMEW G	Person al	Duke Street	Research grant as statistical methodologist/advi sor	Yes
Christina Yap	CTBVEA G, HPMEW G	Person al	Merck	Independent Statistical Consultant; Providing patient- reported outcomes	Yes

methodology
expert advice.

Christina Yap	CTBVEA G, HPMEW G	Person al	Trogenix	Independent Statistical Consultant	Yes
Christina Yap	CTBVEA G, HPMEW G	Non- Person al	AstraZen eca	Trial grant (where I am a co- investigator)	No
Christina Yap	CTBVEA G, HPMEW G	Non- Person al	Plexxikon	Trial grant (where I am a co- investigator)	No

Christopher Weir	CHM, RWDEW G, HPMEW G	Personal	NIL	N/A	N/A
------------------	-----------------------------------	----------	-----	-----	-----

Christopher Weir	CHM, RWDEW G, HPMEW G	Non-Personal	AB Science	DSMB membership for three trials (in ALS, mastocytosis and progressive MS), plus advice on regulatory submissions, resulting in income to my department	Yes
------------------	-----------------------------------	--------------	---------------	--	-----

Christopher Weir	CHM, RWDEWG, HPMEWG	Non-Personal	Eli Lilly	Research grant to institution, on which I am co-applicant	Yes
Christopher Yau	HPMEWG	Personal	NIL	N/A	N/A
Christopher Yau	HPMEWG	Non-Personal	Roche	Roche funded DPhil student to University of Oxford	Yes
Clare Pain	PMEAG	Personal	NIL	N/A	N/A

Clare Pain	PMEAG	Non-Personal	NIL	N/A	N/A
Clare Pain	PMEAG	Additional			Currently have CTIMPS open at our site with following companies (my role stated): Abbvie – site PI for Risankizumab in JIA Amgen – UK CI for paediatric Behcet’s trial of apremilast

(ongoing)

Lilly –

ixekizumab in
JIA – in follow-
up (sub-
investigator)

Roche –

Obinutuzumab
in lupus
nephritis (sub-
investigator)

AstraZeneca –
anifrolumab in
paediatric lupus
(sub-
investigator)

Colin Brown	HPMEWG	Personal	NIL	N/A	N/A
Colin Brown	HPMEWG	Non-Personal	NIL	N/A	N/A
Colin Forfar	RWDEWG	Personal	NIL	N/A	N/A
Colin Forfar	RWDEWG	Non-Personal	NIL	N/A	N/A
Daniel Hawcutt	PEAG, PMEAG, VIEWG	Personal	Steritas	Member of Advisory Panel	Yes

Daniel Hawcutt	PEAG, PMEAG, VIEWG	Non- Person al	NIL	N/A	N/A
-------------------	--------------------------	----------------------	-----	-----	-----

Daniel Hawcutt	PEAG, PMEAG, VIEWG	Additio nal			Director of the NIHR Alder Hey Clinical Research Facility – with approximately 50-60 early phase studies ongoing. I do not get paid for this activity – my time is funded via an NIHR award, but the
-------------------	--------------------------	----------------	--	--	---

trust I work for
(Alder Hey)
does get
commercial
income from
these contracts
(at the set
national NIHR
rates). I declare
any open
studies on
similar or related
products with
any relevant
agenda items as
“non personal
non-specific” in
any committee

where this appears in the agenda.

Daniel Lumsden	PMEAG	Personal	NIL	N/A	N/A
Daniel Lumsden	PMEAG	Conferences/Scientific Meetings	Taysha	Investigators Meeting Taysha TSHA-102 Gene Therapy: Expenses paid to attend investigators meeting. I am CI for this study in the	No

UK (no fees paid for this role)

Daniel Lumsden

PMEAG

Non-Personal

NIL

N/A

N/A

Daniel Lumsden

PMEAG

Additional

Immediate family member works for Sanofi as Head of Regulatory Science and Policy, EU/AMEE Region, who receives a salary from Sanofi, and

Daniel
Lumsde
n

PMEAG

Additional

shares in the
company as part
of remuneration.

I am Chief
Investigator in
the UK for the
REVEAL
Pediatric Study
– Safety and
Efficacy of
TSHA-102 in
Pediatric
Females with
Rett Syndrome.
This study is
sponsored by
Taysha. I have

been CI for this study since MHRA approval was received in January 2024. This study is ongoing.

Darragh Murnane	CPSEAG	Personal	Adare Pharmaceuticals Inc. (New Jersey, USA)	Consultancy	No
Darragh Murnane	CPSEAG	Personal	Informix Pharma Ltd	Personal, Founder and Director	Yes

Darragh Murnane	CPSEAG	Personal	Merxin Ltd.	Non-specific, Scientific Advisory Board Fees	Yes
Darragh Murnane	CPSEAG	Non-Personal	Fluid Pharma Ltd	Non-personal, University Director and no personal benefit	No
Darragh Murnane	CPSEAG	Non-Personal	AstraZeneca	In-kind support for research project at University of Hertfordshire	No
Darragh Murnane	CPSEAG	Non-Personal	Bespak Ltd.	Funding for collaborative research, 2 PhD projects and consultancy	Yes

				performed through University of Hertfordshire	
Darragh Murnane	CPSEAG	Non- Person al	Capitainer Ab	Sponsored research student at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non- Person al	Chiesi Ltd.	Sponsored PhD Student	No
Darragh Murnane	CPSEAG	Non- Person al	Chiesi Ltd.	Speakers fees paid to Informix Pharma Ltd.	No

Darragh Murnane	CPSEAG	Non-Personal	Philips Respironics	Loaned Equipment at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Conferences/Scientific Meetings	Merxin Ltd.	Hospitality at DDL 2024 conference	No
Darragh Murnane	CPSEAG	Conferences/Scientific Meetings	Chiesi Ltd	Chiesi Medical Education programme on Inhaler Resistance: Travel expenses for travel to Manchester to present to	No

				healthcare practitioners' panel	
Darragh Murnane	CPSEAG	Confer ences/ Scienti fic Meetin gs	RDD Online	RDD 2024: Speakers Fees	No
Darragh Murnane	CPSEAG	Confer ences/ Scienti fic Meetin gs	Merxin Ltd	Hospitality at RDD 2024 conference	No

Darragh Murnane	CPSEAG	Conferences/Scientific Meetings	Merxin Ltd	SMI.London: Free Speaker Registration	No
-----------------	--------	---------------------------------	------------	---------------------------------------	----

Darragh Murnane	CPSEAG	Additional			Founder of Informix Pharma Ltd. And the current CEO of Wickham Micro Ltd. Board Member of Informix Pharma Ltd. Wickham Micro Ltd. provide contract
-----------------	--------	------------	--	--	--

analytical services to the pharmaceutical industry.

Darren Ashcroft	PEAG	Personal	NIL	N/A	N/A
Darren Ashcroft	PEAG	Non-Personal	LEO Foundation, Bristol Myers Squibb, Boehringer Ingelheim, Johnson &	Research grant to support the development of the Global Psoriasis Atlas	Yes

Johnson
(Janssen)
, Almirall

David
Crundwe
ll

CHM

Person
al

NIL

N/A

N/A

David
Crundwe
ll

CHM

Non-
Person
al

NIL

N/A

N/A

David
Crundwe
ll

CHM

Additio
nal

Chair of NHS
Clinical Priorities
Advisory Group
(CPAG): Three-
year term until
April 2026

David Dockrell	CHM, IEAG	Personal	NIL	N/A	N/A	
David Dockrell	CHM, IEAG	Non-Personal	Adiso Therapeutics, Inc GlaxoSmithKline Pfizer Inc Chan Zuckerberg Initiative SanterSus AG IPInc Intercept Pharmaceuticals inc	Sponsorship through grants or other support to investigators	No	Industry companies for whom the academic centre I am director of (Centre for Inflammation Research, University of Edinburgh) has current or recent industry sponsorship through grants or other support

Gene
One
Genentec
h Inc
Stryker
Internatio
nal
Sanofi
Pasteur
MSD
Limited
GlaxoSmi
thKline
UCBC
UCB
BioPharm
a Srl
Novartis

to investigators.
Other than those
outlined these
are not direct to
me

Pharma
AG
Galecto
Biotech
AB
Corin Ltd
Scottish
Power
Astra
Zeneca
Canon
Gene cell
catapult

David
Dockrell

CHM,
IEAG

Non-
Personal

GSK

Access to
compounds for
research by own

Yes

Commitment to
continue to
provide further
agonist

personal group
and collaborators.

compounds on
ongoing MRC
Programme
grant awarded
May 2022.
No direct
financial benefit,
in kind
contribution of
compounds.

David
Dockrell

CHM,
IEAG

Non-
Person
al

Astra
Zeneca

Advisor on a
research project

Yes

I have reviewed
and been
included on a
research
publication-not
yet published.
No financial

David Dockrell	CHM, IEAG	Non-Personal	Moderna, Infex Therapeutics, Cell and Gene Therapy Catapult, PLEX	Access to product pipeline	Yes	<p>benefit</p> <p>Historical link but papers not yet published if company even decide to publish.</p> <p>I lead an MRC CoRE application. The named companies are named as potential partners in the bid. They state they will share</p>
----------------	-----------	--------------	---	----------------------------	-----	---

expertise,
provide training,
advise on
potential
translational
strategies and
give access to
their product
pipeline or in
case of PLEX to
their AI platform
to help the
academic
partners
(Edinburgh,
Oxford, Sheffield
and Malawi
Liverpool

Wellcome Trust
 Centre to
 develop their
 findings as host
 based
 immunotherape
 utics to retune
 innate immune
 responses to
 infection.

David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Person al	NIL	N/A	N/A
David Hunt	CHM, NPPEAG,	Confer ences/ Scienti	Portugues e Multiple Sclerosis	GEEM Spring Meeting (Portugal):	No

	VIEWWG, VEEWG	fic Meetin gs	Study Group	Accommodation and travel		
David Hunt	CHM, NPPEAG, VIEWWG, VEEWG	Non- Person al	NIL	N/A		N/A
David Hunt	CHM, NPPEAG, VIEWWG, VEEWG	Additio nal				Provided advice to Moderna on safety aspects of clinical trial design (unremunerated) .
David Hunt	CHM, NPPEAG,	Additio nal				Spoken at a number of

VIEWG,
VEEWG

multiple
sclerosis
meetings which
have received
sponsorship
from the
pharmaceutical
industry
(unremunerated)

David
Hunt

CHM, Additio
NPPEAG, nal
VIEWG,
VEEWG

Lead NHS
multiple
sclerosis
services within
the Anne
Rowling Clinic in
Edinburgh. The

Anne Rowling
Clinic is
supported by a
philanthropic gift
from JK Rowling
to the University
of Edinburgh.

David Kessler	ARMEW G	Person al	NIL	N/A	N/A
David Kessler	ARMEW G	Non- Person al	NIL	N/A	N/A
David Millrine	HPMEW G	Person al	NIL	N/A	N/A

David Millrine	HPMEWG	Non-Personal	NIL	N/A	N/A	
David Moore	CHM	Personal	NIL	N/A	N/A	
David Moore	CHM	Non-Personal	NIL	N/A	N/A	
David Owens	NPPEAG, VIEWG, ARMEWG	Personal	NIL	N/A	N/A	
David Owens	NPPEAG, VIEWG,	Non-Personal	TEVA	NIL – telephone discussion only	No	I had a single telephone conversation with a senior

ARMEW
G

medical advisor
to Teva on the
general topic of
tardive
dyskinesia, on
which I have
authored a text
and in relation to
which this
company has a
product being
considered for
marketing in the
UK. No
remuneration or
other
blandishments
were offered or

sought and I
have had no
further contact.

David Taylor	ARMEW G	Person al	Janssen- Cilag Ltd	Grant	Yes
David Taylor	ARMEW G	Person al	Otsuka	Grant	No
David Taylor	ARMEW G	Person al	Viatrix	Consultancy	Yes
David Taylor	ARMEW G	Person al	Merck	Consultancy	No
David Taylor	ARMEW G	Person al	Idorsia	Consultancy	Yes

David Taylor	ARMEWG	Personal	428 Pharma	Shares	Yes
David Taylor	ARMEWG	Personal	Myogenes	Shares	Yes
David Taylor	ARMEWG	Personal	Saladax	Shares	Yes
David Taylor	ARMEWG	Non-Personal	NIL	N/A	N/A
David Turner	HPMEWG	Personal	NIL	N/A	N/A
David Turner	HPMEWG	Non-Personal	NIL	N/A	N/A

Debashi Sarker	OHEAG	Personal	AstraZeneca	Advisory Board	Yes
Debashi Sarker	OHEAG	Personal	Servier	Invited speaker, advisory board	Yes
Debashi Sarker	OHEAG	Personal	Eisai	Invited speaker, advisory board	Yes
Debashi Sarker	OHEAG	Personal	Ipsen	Invited speaker	Yes
Debashi Sarker	OHEAG	Conferences/Scientific Meetings	Ipsen	European NET Society (ENETS) Annual Meeting: Travel, conference and hotel expenses	No

Debashi Sarker	OHEAG	Conferences/Scientific Meetings	Servier	European Society Medical Oncology Annual Meeting: Travel, conference and hotel expenses	No
Debashi Sarker	OHEAG	Non-Personal	UCB Biopharma	Research fellowship grants to KCL	Yes
Deborah Ashby	RWDEWG	Personal	NIL	N/A	
Deborah Ashby	RWDEWG	Non-Personal	NIL	N/A	

Deborah
Ashby

RWDEW
G

Additio
nal

From January 2024, I have been Dean of the Faculty of Medicine at Imperial College London. Some staff hold grants, consultancies etc but I have had no direct involvement in those.

Diana
Wellesle
y

MWHEA
G

Person
al

NIL

N/A

N/A

Diana Wellesley	MWHEAG	Non-Personal	NIL	N/A	N/A
Ellie Gordon	CHM, ARMEWG	Personal	NIL	N/A	N/A
Ellie Gordon	CHM, ARMEWG	Non-Personal	NIL	N/A	N/A
Eric Lim	HPMEWG	Personal	AstraZeneca	Consultancy, advisory board, fee paid education, NICE expert advisor	No

Eric Lim	HPMEW G	Person al	Boehringer r Ingelheim	Consultancy	No
Eric Lim	HPMEW G	Person al	Medela	Consultancy, advisory board, fee paid education	No
Eric Lim	HPMEW G	Person al	Beigene	Consultancy	No
Eric Lim	HPMEW G	Person al	Roche	Consultancy, advisory board, fee paid education	No
Eric Lim	HPMEW G	Person al	BMS	Consultancy, advisory board, fee paid education	No

Eric Lim	HPMEWG	Personal	Merck Sharp and Dohme	Advisory board	No
Eric Lim	HPMEWG	Non-Personal	AstraZeneca	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Lilly	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Bayer	Unrestricted grant	No

Eric Lim	HPMEWG	Non-Personal	Boehringer Ingelheim	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Takeda	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Roche	Unrestricted grant	No
Farzin Farzaneh	CTBVEAG	Personal	Apterna	Consultancy	Yes
Farzin Farzaneh	CTBVEAG	Personal	Autolus, UK	Shares	No

Farzin Farzaneh	CTBVEA G	Person al	VacV Therapeutics	Consultant	Yes
Farzin Farzaneh	CTBVEA G	Person al	Dawn Therapeutics	Consultancy and Shares	Yes
Farzin Farzaneh	CTBVEA G	Person al	ViroCell Biologics Ltd	Appointed as the Chief Scientific Officer. I am also a Co-Founder and Shareholder	Yes
Farzin Farzaneh	CTBVEA G	Person al	King's College London	Part-time Professor of Molecular Medicine	Yes

Farzin Farzaneh	CTBVEA G	Person al	Guys Hospital NHS Trust	Qualified Person	Yes
Farzin Farzaneh	CTBVEA G	Person al	University of Dresden, Germany	Trans-Campus Professor of Molecular Medicine, in partnership with King's College London	No
Farzin Farzaneh	CTBVEA G	Person al	Great Ormond Street Hospital	Qualified Person	Yes

NHS
Trust

Farzin Farzaneh	CTBVEAG	Personal	Imperial College London	Visiting Professor of Molecular Medicine	Yes
Farzin Farzaneh	CTBVEAG	Personal	University College London	Honorary Professor of Molecular Medicine	Yes
Farzin Farzaneh	CTBVEAG	Non-Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Personal	NIL	N/A	N/A

Federico Brucoli	CPSEAG	Non- Person al	NIL	N/A	N/A
Fergus Rugg- Gunn	NPPEAG	Person al	NIL	N/A	N/A
Fergus Rugg- Gunn	NPPEAG	Non- Person al	NIL	N/A	N/A
Finbar O'Callag han	VIEWWG	Person al	NIL	N/A	N/A
Finbar O'Callag han	VIEWWG	Non- Person al	NIL	N/A	N/A

Fraz Mir	PEAG	Personal	BNF	Chair of BNF Formulary Committee: Honorarium	Yes
Fraz Mir	PEAG	Conferences/Scientific Meetings	AstraZeneca	Cambridge Medical Seminars Conference: grant and venue for meeting	No
Fraz Mir	PEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Personal	NIL	N/A	N/A

Geraint Davies	IEAG	Non- Person al	NIL	N/A	N/A
-------------------	------	----------------------	-----	-----	-----

Geraint Davies	IEAG	Additio nal			I was the academic co- ordinator of the PreDiCT-TB consortium, a public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of
-------------------	------	----------------	--	--	--

Pharmaceutical
Industries and
Associations.
However,
though this role
involved
engagement
with industrial
partners (GSK,
Sanofi, Janssen)
in pre-
competitive
areas of
research into TB
drug
development,
these activities
were fully

Geraint
Davies

IEAG

Additional

supported by public funding from the EU and neither myself nor my research institution received any funding from EFPIA or from the individual industrial partners.

Since 2017 I have been an academic partner to the PanACEA

clinical trials
consortium,
funded by the
European and
Developing
Countries
Clinical Trials
Partnership.
Though the
consortium has
involved contact
and
collaboration
with
pharmaceutical
partners, my
role at the
University of

Liverpool is as a partner without budget supporting the clinical trials site at the College of Medicine in Blantyre, Malawi. Neither myself, the University of Liverpool nor the University of Malawi College of Medicine receive any funding from pharmaceutical

Geraint
Davies

IEAG

Additional

collaborators as
part of these
activities.

Since 2020 I
have been an
academic
partner to the
UNITE4TB
consortium, a
new public-
private
partnership
funded by the
European Union
Innovative
Medicines
Initiative and the

European
Federation of
Pharmaceutical
Industries until
2028. However,
though this role
involves
engagement
with industrial
partners (GSK,
Janssen,
Evotec) in pre-
competitive
areas of
research into TB
drug
development,
these activities

are fully supported by public funding from the EU and neither myself nor my research institution receive any funding from EFPIA or from the individual industrial partners.

Geraint
Davies

IEAG

Additional

I have attended expert advisory meetings relating to TB

Gerri
Mortimor
e

CHM

Person NIL
al

N/A

N/A

drug
development
convened by
GSK and
Janssen for
which I received
no payment or
benefit
(honorarium,
expenses,
hospitality)

Gerri Mortimore	CHM	Conferences/Scientific Meetings	Mark Allen publishing group (GIN Journal)	Gastrointestinal Nursing conference: one of the speakers on the day as well as invited panel expert. MAG paid Hotel fee and return train fare. No payment was given for speaking as this is recognised as part of my Professional role as associate professor at a HEI.	No
-----------------	-----	---------------------------------	---	--	----

Gerri Mortimore	CHM	Non-Personal	NIL	N/A	N/A
Glyn Lewis	ARMEWG	Personal	ECNP 2023	Travel and accommodation for attending the European College of Neuropsychopharmacology	No
Glyn Lewis	ARMEWG	Personal	Fortitude law	Paid for expert advice to a litigation concerned with paroxetine withdrawal	Yes

			symptoms in relation to GSK	
Glyn Lewis	ARMEWG	Personal NIHR	Funded as Chief Investigator to investigate pregabalin for treating anxiety in those not responding to antidepressants (PETRA)	Yes
Glyn Lewis	ARMEWG	Personal NIHR	Funded as chief investigator to investigate sertraline for depressive symptoms in	

				primary care (PANDA RCT)	
Glyn Lewis	ARMEWG	Personal	NIHR	Co-applicant on NIHR grant	Yes
Glyn Lewis	ARMEWG	Personal	NIHR	Chief investigator on NIHR grant	No
Glyn Lewis	ARMEWG	Conferences/ Scientific Meetings	NIL	N/A	N/A
Glyn Lewis	ARMEWG	Non-Personal	NIL	N/A	N/A

Guido Pieleles	PMEAG	Personal	Pharmacia	Consultant advisor in regulatory proceedings	Yes
Guido Pieleles	PMEAG	Personal	Canon Medical Systems	Development of hard and software consultant and lecturer	No
Guido Pieleles	PMEAG	Non-Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Non-Personal	NIL	N/A	N/A

Hannah Batchelor	CPSEAG	Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Non-Personal	UCB	Grant awarded to support a PhD student under my supervision	No
Hannah Batchelor	CPSEAG	Non-Personal	GSK	Grant awarded to support a PhD student under my supervision	Yes
Hassan Kahal	CDRRA EAG	Personal	NIL	N/A	N/A

Hassan Kahal	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Hassan Kahal	CDRRA EAG	Additional			Investigator (principal investigator and sub-investigator) on a number of commercial and non-commercial multi-centre clinical research trials related to obesity and diabetes conducted at the Diabetes

research centre
at North Bristol
NHS Trust.
Family member
works for Novo
Nordisk in drug
development but
this has no
impact on my
clinical decision
making. I
received no
personal
payment,
honoraria, or
travel support
from any

pharmaceutical
company

Heather Wallace CHM, VEEWG Personal NIL N/A N/A

Heather Wallace CHM, VEEWG Non-Personal NIL N/A N/A

Heather Wallace CHM, VEEWG Additional I am Chair of Medical Research Scotland. We fund PhD studentships, and each studentship has an external partner

organisation
(EPO). This can
be industry or
charity. The
relationship is
between the
student,
supervisor and
university.
Medical
Research
Scotland
provides funds to
the University
who funds the
student but has
no relationship

with the student
or the EPO.

Hoo Kee Tsang	NPPEAG, ARMEW G	Person al	NIL	N/A	N/A
Hoo Kee Tsang	NPPEAG, ARMEW G	Non- Person al	NIL	N/A	N/A
Jacqueli ne McMurtri e	PMEAG	Person al	NIL	N/A	N/A
Jacqueli ne	PMEAG	Non- Person al	NIL	N/A	N/A

McMurtrie

Jacqueline
McMurtrie

PMEAG

Additional

.

Director at WRK
Orthopedics
which is family
member's
private practice -
have no
involvement with
any
pharmaceuticals
companies.

Jacqui
Shaw

HPMEWG

Personal

ThermoFisher

Reagents to
support early
access
programme

Yes

Jacqui Shaw	HPMEWG	Personal	AstraZeneca	Research grant	No
Jacqui Shaw	HPMEWG	Personal	Nonacus	Reagents to support product development and validation	Yes
Jacqui Shaw	HPMEWG	Non-Personal	NIL	N/A	N/A
James Pitayanukul	GRID EAG	Personal	NIL	N/A	N/A
James Pitayanukul	GRID EAG	Non-Personal	NIL	N/A	N/A

James Pitayanu kul	GRID EAG	Additio nal
--------------------------	-------------	----------------

Treasurer of the National Eczema Society, a charity registered in the UK. I am a Partner in accountancy firm, P and Co (Partners) LLP. I am a director of three limited companies: P and Co Services Ltd, Eczema Trading Limited and Good UK

Properties
Limited.

James Spicer	OHEAG, HPMEWG	Personal	Epsilogen Ltd, co-founder	Stock ownership	Yes
James Spicer	OHEAG, HPMEWG	Personal	APOBEC Discovery Ltd	Board Membership	Yes
James Spicer	OHEAG, HPMEWG	Personal	Achilles	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Gilead	Reimbursement to my institution for	Yes

				recruitment to clinical trials	
James Spicer	OHEAG, HPMEW G	Person al	IO Biotech	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEW G	Person al	MSD	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEW G	Person al	Roche	Reimbursement to my institution for recruitment to clinical trials	Yes

James Spicer	OHEAG, HPMEWG	Personal	RS Oncology	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Starpharma	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Avacta Ltd	Stock ownership	Yes
James Spicer	OHEAG, HPMEWG	Conferences/Scientific	Starpharma	ASCO Annual Meeting: Assistance with attendance at	No

		Meetings		international meetings	
James Spicer	OHEAG, HPMEWG	Conferences/Scientific Meetings	RS Oncology	ASCO Annual Meeting: Assistance with attendance at international meetings	No
James Spicer	OHEAG, HPMEWG	Non-Personal	APOBEC Discovery Ltd	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non-Personal	AstraZeneca	Reimbursement to my institution for advisory role	Yes

James Spicer	OHEAG, HPMEWG	Non-Personal	BMS	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non-Personal	Roche	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non-Personal	BioNTech	Reimbursement to my institution for advisory role	Yes
Jamie Coleman	CHM, PEAG, HPMEWG	Personal	NIL	N/A	N/A

Jamie Coleman	CHM, PEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Jamie Fraser	CHM, ARMEWG	Personal	NIL	N/A	N/A
Jamie Fraser	CHM, ARMEWG	Non-Personal	NIL	N/A	N/A
Janet Brown	OHEAG	Personal	Ipsen	Consultancy, advisory boards, travel support to conference	Yes

Janet Brown	OHEAG	Personal	Eisai	Consultancy, advisory boards	Yes
Janet Brown	OHEAG	Personal	Osteolabs	Consultancy (Fee to my employer)	Yes
Janet Brown	OHEAG	Non-Personal	NIL	N/A	N/A
Janet Darbyshire	RWDEWG	Personal	NIL	N/A	N/A
Janet Darbyshire	RWDEWG	Non-Personal	NIL	N/A	N/A

John Petrie	CDRRA EAG	Personal	Boehringer- Ingelheim	Endpoint Committee for trials (personal fees for Consultancy via University of Glasgow)	Yes
John Petrie	CDRRA EAG	Personal	Merck KGaA	Honorarium for review article commissioned by Diabetes, Obesity and Metabolism for special issue funded by Merck KGAA	No

John Petrie	CDRRA EAG	Personal	Sanofi	Attended Sanofi Advisory Board for expert opinion management	No
John Petrie	CDRRA EAG	Conferences/Scientific Meetings	Sanofi	European Association for the Study of Diabetes: Registration, accommodation, travel	No
John Petrie	CDRRA EAG	Non-Personal	Novo Nordisk	Donation of IMP for investigator-led trial (compassionate due to market supply issues)	Yes

Jon Deeks	HPMEWG	Personal	NIL	N/A	N/A
Jon Deeks	HPMEWG	Non-Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Non-Personal	NIL	N/A	N/A
Jonathan Lord	MWHEAG	Additional			Additional national roles held (all honorary): Co-chair, Royal College of

Obstetricians &
Gynaecologists
(RCOG)
abortion
taskforce
Chair, quality
committee,
British Society of
Abortion Care
Providers
(BSACP); co-
chair of BSACP
until November
2024
Past roles and
academic work
including
publications,

national
guideline
committees,
development of
position
statements etc.
is given at
[https://orcid.org/
0000-0003-
2819-5973](https://orcid.org/0000-0003-2819-5973).

Julia
Cons

CHM,
HPMEW
G,
VEEWG

Person NIL
al

N/A

N/A

Julia Cons	CHM, HPMEW G, VEEWG	Non- Person al	NIL	N/A	N/A
Julia Cons	CHM, HPMEW G, VEEWG	Additio nal			I am vice chair of the Ministry of Defence Research Ethics Committee. I think a conflict of interests is extremely unlikely to arise. However, if any opportunity were to arise for any perceived

Julia
Cons

CHM,
HPMEW
G,
VEEWG

Additio
nal

conflict, I would
absent myself
from any
discussions.

I am
Independent
Chair of NHS
England's
Individual
Funding
Request Panel. I
see no obvious
opportunity for a
conflict of
interests to
arise.

Julia Cons	CHM, HPMEW G, VEEWG	Additio nal	I chaired the NICE Management of Acne Guideline Committee until. The Guideline published in June 2021 so I see no opportunity for a conflict of interests to arise.
---------------	------------------------------	----------------	---

Julia Cons	CHM, HPMEW G, VEEWG	Additio nal	I was a member and deputy chair of the NICE Self-harm:
---------------	------------------------------	----------------	---

Assessment, Management and Preventing Recurrence Guideline Committee. The Guideline published in July 2022 so I see no opportunity for a conflict of interests to arise.

I am vice chair, and during 2024 was acting chair of NHS

Julia Cons	CHM, HPMEW G, VEEWG	Additio nal
---------------	------------------------------	----------------

England's
Specialised
Commissioning
Patient and
Public Voice
Assurance
Group. I see no
obvious
opportunity for a
conflict of
interests to
arise.

Julia Prague	MWHEA G	Person al	AstraZen eca	Immediate family member holds shares	Yes
-----------------	------------	--------------	-----------------	--	-----

Julia Prague	MWHEA G	Personal	Synairgen	Immediate family member holds shares	Yes
Julia Prague	MWHEA G	Personal	Sareum Holdings	Immediate family member holds shares	Yes
Julia Prague	MWHEA G	Personal	GSK	Immediate family member holds shares	Yes
Julia Prague	MWHEA G	Personal	Haleon	Immediate family member holds shares	Yes
Julia Prague	MWHEA G	Non-Personal	NIL	N/A	N/A

Julia Prague	MWHEAG	Additional					I am an Associate Editor of Endocrine Related Cancer Journal (not associated with any financial remuneration)
Julia Taylor	PMEAG	Personal	NIL		N/A		N/A
Julia Taylor	PMEAG	Non-Personal	NIL		N/A		N/A
Kathryn Johnson	PMEAG	Personal	NIL		N/A		N/A

Kathryn Johnson	PMEAG	Non- Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Non- Personal	NIL	N/A	N/A
Kevin Taylor	HPMEWG	Personal	NIL	N/A	N/A
Kevin Taylor	HPMEWG	Non- Personal	NIL	N/A	N/A
Kim Morley	VIEWG	Personal	NIL	N/A	N/A

Kim Morley	VIEWG	Non- Personal	NIL	N/A	N/A
Kirstie Shearman n	CTBVEA G	Personal	NIL	N/A	N/A
Kirstie Shearman n	CTBVEA G	Non- Personal	NIL	N/A	N/A
Laura Magee	MWHEA G	Personal	Nightingale Medical	Shares	Yes
Laura Magee	MWHEA G	Non- Personal	NIL	N/A	N/A

Laurie Tomlinson	MWHEAG	Personal	NIL	N/A	N/A
Laurie Tomlinson	MWHEAG	Non-Personal	NIL	N/A	N/A
Lim Jones	IEAG	Personal	NIL	N/A	N/A
Lim Jones	IEAG	Non-Personal	NIL	N/A	N/A
Linda Pepper	MWHEAG, ARMEWG	Personal	NIL	N/A	N/A

Linda Pepper	MWHEA G, ARMEW G	Non- Person al	NIL	N/A	N/A
-----------------	---------------------------	----------------------	-----	-----	-----

Linda Pepper	MWHEA G, ARMEW G	Additio nal			Lay Examiner with RCOG part 3 MRCOG exams A public member of Secure Data Environment with North East + North Cumbria ICB A public governor with
-----------------	---------------------------	----------------	--	--	---

Newcastle
Hospital NHS
Trust

Lisa Brownell	NPPEAG	Personal	NIL	N/A	N/A
Lisa Brownell	NPPEAG	Non- Personal	NIL	N/A	N/A
Louis Grandjean	IEAG	Personal	Shionogi	Grant	Yes
Louis Grandjean	IEAG	Personal	Pfizer	Grant	Yes

Louis Grandjean	IEAG	Personal	Advanzal	Grant	Yes
Louis Grandjean	IEAG	Personal	Mundipharma	Grant	Yes
Louis Grandjean	IEAG	Conferences/Scientific Meetings	Pfizer	Start Meeting: Support for the meeting, travel for speakers and catering costs	No
Louis Grandjean	IEAG	Non-Personal	NIL	N/A	N/A

Louise Massey	MWHEA G	Personal	NIL	N/A	N/A
Louise Massey	MWHEA G	Non-Personal	NIL	N/A	N/A
Louise Massey	MWHEA G	Additional			I was a committee member in the NICE Menopause Guideline 23 update completed in November 2024. Meetings and email exchanges

regarding the guideline took place between 1.1.24 and 1.7.24. This guideline is now published and the work complete.

Member 4	VIEWWG	Personal	NIL	N/A	N/A
Member 4	VIEWWG	Non-Personal	NIL	N/A	N/A

Lucy Mackillop	MWHEAG	Personal	Sensyne Health plc	Shareholder	No
Lucy Mackillop	MWHEAG	Personal	Oxford University Innovation	Payment for royalties	No
Lucy Mackillop	MWHEAG	Personal	EMIS group plc	Paid employee and Shareholder	Yes
Lucy Mackillop	MWHEAG	Non-Personal	NIL	N/A	N/A

Luigi (Gino) Martini	CPSEAG	Person al	GSK	Shares with GSK and pension	Yes	
Luigi (Gino) Martini	CPSEAG	Person al	GSK, MSD, Becton Dickinson , Pinsent Masons, Knobbe Martin	Own consultancy- Lupa Medical	Yes	Private consultancy owned by member
Luigi (Gino) Martini	CPSEAG	Person al	Bioemolo us Ltd	Advise on hypochlorous acid sanitiser	Yes	Private consultancy owned by member

Luigi (Gino) Martini	CPSEAG	Personal	Colltech Labs	Unpaid but minor share holder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Biotherapy Services Ltd	Unpaid but minor share holder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Altabiome Therapeutics Ltd	Unpaid but share holder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Lakes Biosciences Ltd	Unpaid but share holder	Yes

Luigi (Gino) Martini	CPSEAG	Personal	Nash Therapeutics Ltd	Unpaid but share holder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Biosimax Ltd	Unpaid but share holder	Yes
Luigi (Gino) Martini	CPSEAG	Non- Personal	GSK	Funded 2 PhD case awards	No
Luigi (Gino) Martini	CPSEAG	Non- Personal	Gamlen Tabletting /German Government	Funded fellowships to examine tabletting	No

Luigi (Gino) Martini	CPSEAG	Non- Person al	Dr Reddys	Funded research programme	No	
Luigi (Gino) Martini	CPSEAG	Non- Person al	Saudi Governm ent	Funded PhD award	No	
Luigi (Gino) Martini	CPSEAG	Non- Person al	Mexican Governm ent	Funded PhD award	No	
Luigi (Gino) Martini	CPSEAG	Additio nal				Immediate family member used to work for GSK, has GSK and SB shares as well as pension.

Ly-Mee Yu	HPMEWG	Personal	NIL	N/A	N/A
Ly-Mee Yu	HPMEWG	Non-Personal	NIL	N/A	N/A
Madeleine Wang	PEAG	Personal	NIL	N/A	N/A
Madeleine Wang	PEAG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Non-Personal	NIL	N/A	N/A

Majella
Lane CPSEAG Additional

I have established a limited company called Melderm Ltd. The company provides expert witness services for patent matters in the United States.

Malcolm Oswald PEAG Personal NIL N/A N/A

Malcolm Oswald PEAG Non-Personal NIL N/A N/A

Marc Turner	CHM, CTBVEA G, HPMEW G	Personal	NIL	N/A	N/A
Marc Turner	CHM, CTBVEA G, HPMEW G	Non-Personal	Resolution Therapeutics	SNBTS manufacture for first in human clinical trial.	Yes
Mark Evans	CDRRA EAG	Personal	Abbott Diabetes Care	(1) Speakers fees, (2) sponsorship for Clinical triallist on a multicentre study	No
Mark Evans	CDRRA EAG	Personal	Eli Lilly	Speakers Fees	No

Mark Evans	CDRRA EAG	Person al	Pila Pharma	(1) Advisory board (2) Planned clinical trialogist	No
Mark Evans	CDRRA EAG	Person al	Zucara	Advisory Board	No
Mark Evans	CDRRA EAG	Person al	Sanofi	(1) Advisory boards (2) Planned speakers fees	No
Mark Evans	CDRRA EAG	Person al	Vertex	(1) Advisory board	No
Mark Evans	CDRRA EAG	Confer ences/ Scienti fic	Eli Lilly	Travel expenses and speaker's fee as above	Yes

Meetings

Mark Evans	CDRRA EAG	Non-Personal	Abbott Diabetes Care	Clinical triallist	No
Mark Evans	CDRRA EAG	Non-Personal	NovoNordisk	Sponsored PhD studentship as supervisor	No
Mark Evans	CDRRA EAG	Non-Personal	Lexicon	Planned clinical triallist	No
Martin English	PMEAG	Personal	NIL	N/A	N/A

Martin English	PMEAG	Non-Personal	NIL	N/A	N/A
Martin Wilson	CHM, VIEWG	Personal	NIL	N/A	N/A
Martin Wilson	CHM, VIEWG	Non-Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Non-Personal	NIL	N/A	N/A

Michael Ardern- Jones	GRIDEA G	Person al	Sanofi- Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person al	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person al	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes

Michael Ardern- Jones	GRIDEA G	Person al	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person al	Lilly	Consultancy, Advisory board fees	Yes
Michael Ardern- Jones	GRIDEA G	Person al	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person al	Almirall	Consultancy, Advisory board fees, Conference	Yes

				attendance, Speaker fees	
Michael Ardern- Jones	GRIDEA G	Person Galderma al		Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person Novartis al		Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Person Regenero al n		Consultancy, Advisory board fees, Conference	Yes

				attendance, Speaker fees	
Michael Ardern- Jones	GRIDEA G	Confer ences/ Scienti fic Meetin gs	Sanofi- Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Confer ences/ Scienti fic Meetin gs	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes

Michael Ardern- Jones	GRIDEA G	Confer ences/ Scienti fic Meetin gs	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Confer ences/ Scienti fic Meetin gs	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern- Jones	GRIDEA G	Confer ences/ Scienti fic	Lilly	Consultancy, Advisory board fees	Yes

Meetings

Michael Ardern-Jones	GRIDEA G	Conferences/Scientific Meetings	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
----------------------	----------	---------------------------------	-------------------------	---	-----

Michael Ardern-Jones	GRIDEA G	Conferences/Scientific Meetings	Almirall	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
----------------------	----------	---------------------------------	----------	---	-----

Michael Ardern-Jones	GRIDEA G	Conferences/Scientific Meetings	Galderma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEA G	Conferences/Scientific Meetings	Novartis	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEA G	Conferences/Scientific	Regeneron	consultancy, Advisory board fees, Conference	Yes

Meetings
attendance,
Speaker fees

Michael Ardern-Jones GRIDEA G Non-Personal Ducentis UoS collaboration research Yes

Michael Ardern-Jones GRIDEA G Non-Personal Almirall UHS Commercial clinical trial Yes

Michael Ardern-Jones GRIDEA G Non-Personal Abbvie UHS Commercial clinical trial Yes

Michael Ardern-Jones GRIDEA G Non-Personal Leo Pharma UHS Commercial clinical trial Yes

Michael Ardern-Jones	GRIDEA G	Non-Personal	Leo Pharma	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEA G	Non-Personal	Amgen	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEA G	Non-Personal	Sanofi	UoS collaboration research, UHS Commercial Trial	Yes
Michael Ardern-Jones	GRIDEA G	Non-Personal	Pfizer	UoS collaboration research	Yes
Michael Ardern-Jones	GRIDEA G	Additional			Biotechnology and Biological Sciences Research

Michael
Ardern-
Jones

GRIDEA
G

Additio
nal

Council iCASE
industrial
studentships
have been
funded at my
institution with
Unilever. I
supervised
PhDs. Unilever
is a consumer
goods
manufacturer,
with an interest
in skin science.

I have
collaborated
with Emblation

(unpaid), and have received small donations towards my research programme.

Michael Brown	IEAG	Personal	NIL	N/A	N/A
Michael Brown	IEAG	Non-Personal	GSK	The Infection Division at UCLH for which I am DCD, received funds for recruitment of patients into the LUNAR SARS-CoV-2 variant	No

				monitoring study. I was local PI	
Michael Brown	IEAG	Non-Personal	AstraZeneca	The Infection Division at UCLH for which I am DCD, received funds for recruitment of patients into the TILIA study of this anti-IL33 drug. I am local PI	Yes
Michael Brown	IEAG	Non-Personal	Gilead	The Infection Division at UCLH for which I am DCD, received funds for	Yes

recruitment of patients into the inpatient and outpatient remdesivir trials. I was local PI for 3 trials and UK CI for one trial

Michael Steiner	CDRRA EAG	Personal	NIL	N/A	N/A
Michael Steiner	CDRRA EAG	Conferences/ Scientific Meetings	AstraZeneca	Long term conditions conference: Expenses to attend conference only	No

Michael Steiner	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Morris Zwi	ARMEWG	Personal	NIL	N/A	N/A
Morris Zwi	Morris Zwi	Non-Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG	Non-Personal	Astra Zeneca	Research grant to University of Liverpool (UoL), University of	Yes

G, RWD
EWG

Manchester
(UoM), University
of Glasgow (UoG)
and Queen Mary
University London
(QMUL) to support
clinical fellowships
jointly with UK
Medical Research
Council (MRC)

Munir
Pirmoha
med

CHM,
HPMEW
G, RWD
EWG

Non-
Person
al

Eli Lilly

Research grant to
Universities of
Liverpool (UoL)
and Manchester
(UoM) to support
clinical training
fellowships jointly

Yes

				with UK Medical Research Council (MRC)	
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Novartis	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Roche	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, HPMEWG	Non-Personal	Closed Loop Medicine	Sharing of data on oral anticoagulants	Yes

	G, RWD EWG			– no funding provided	
Munir Pirmoha med	CHM, HPMEW G, RWD EWG	Non- Person al	UCB Pharma	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes
Munir Pirmoha med	CHM, HPMEW G, RWD EWG	Non- Person al	GSK	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support	Yes

				clinical fellowships jointly with UK Medical Research Council (MRC)	
Munir Pirmoha med	CHM, HPMEWG, RWD EWG	Non-Personal	Optum	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK	Yes

				Medical Research Council (MRC)	
Munir Pirmohamed	CHM, HPMEWG, RWD, EWG	Non-Personal	Hammersmith Medicines Research	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes

Munir	CHM,	Additio
Pirmoha	HPMEW	nal
med	G, RWD	
	EWG	

I am part of the IMI Consortium called ARDAT (<https://ardat.org/>). As is well known, this is partnership funding for research through the EU Commission, with academic partners like myself receiving funding via the EU (to the University of Liverpool), while

Industry partners provide their expertise as an in-kind contribution. The companies involved in the IMI programme are:
Pfizer/Bayer/Jan
ssen/Pharmace
utica NV /Lonza
AG /Novartis
/Novo Nordisk
/Sanofi-Aventis
/Spark
Therapeutics,
Inc /Takeda

Munir CHM, Additio
Pirmoha HPMEW nal
med G, RWD
EWG

Pharmaceuticals
International AG
/Viscofan SA
/Astellas
Pharma Europe
BV /Roche
These are
declared as
NP/NS when
any of their
products come
up on the
agenda.

I have been
appointed as
Chair of the Prix
Galien UK prize

Munir CHM, Additio
Pirmoha HPMEW nal
med G, RWD
EWG

awarding
committee from
September
2023.

I am a Medical
Trustee for the
British Heart
Foundation, and
a member of the
governing
council of the
Medical
Research
Council. I was
President of the
Association of
Physicians until

May 2024. I have also advised the Qatar Precision Health Initiative and the Bosch Health Foundation on research related to personalised medicine and pharmacogenomics.

Naomi NPPEAG, Person NIL
Fineberg VIEWG al

N/A

N/A

Naomi Fineberg	NPPEAG, VIEWG	Confer ences/ Scienti fic Meetin gs	European College of Neuropsy chopharm acology Annual Congress	Expenses	No
-------------------	------------------	--	---	----------	----

Naomi Fineberg	NPPEAG, VIEWG	Confer ences/ Scienti fic Meetin gs	British Associatio n for Psychoph armacolo gy Annual Summer Meeting	Expenses	No
-------------------	------------------	--	--	----------	----

Naomi Fineberg	NPPEAG, VIEWG	Confer ences/ Scienti fic Meetin gs	British Associatio n for Psychoph armacolo gy Mastercla ss	Expenses	No
-------------------	------------------	--	---	----------	----

Naomi Fineberg	NPPEAG, VIEWG	Confer ences/ Scienti fic Meetin gs	Internatio nal College of Neuropsc hopharma cology Annual Congress	Expenses	No
-------------------	------------------	--	---	----------	----

Naomi Fineberg	NPPEAG, VIEWG	Confer ences/ Scienti fic Meetin gs	Portugues e Society of Psychiatr y and Mental Health	Expenses	No
-------------------	------------------	--	--	----------	----

Naomi Fineberg	NPPEAG, VIEWG	Non- Person al	Biohaven	Corporate membership fees were paid to the International College of Obsessive- Compulsive Spectrum Disorders (ICOCS), a	No
-------------------	------------------	----------------------	----------	--	----

medical
charity, of which I
am the
secretary

Naomi Fineberg	NPPEAG, VIEWWG	Non- Person al	Compass Pathways	The company provided the drug for a research project i had a research role in	No
-------------------	-------------------	----------------------	---------------------	---	----

Naomi Fineberg	NPPEAG, VIEWWG	Additio nal			I work as a clinical lead of an NHS England service providing pharmacological treatment for obsessive
-------------------	-------------------	----------------	--	--	--

compulsive disorders. I act as an unpaid medical adviser and trustee to national consumer charities for OCD and related disorders. I co-chair the World Psychiatric Association scientific section on anxiety, OCD and related disorders. I have

contributed to
the current
British
Association For
Psychopharmac
ology (BAP)
treatment
guidelines for
anxiety
disorders (2014)
and the NICE
treatment
guidelines
including the
most recent
update (2013). I
chair the
external review

board of the
European
College Of
Neuropsychoph
armacology
(ECNP). I am
secretary of the
International
College Of
Obsessive-
Compulsive
Spectrum
Disorders
(ICOCS), which
has received
corporate
membership
fees from

Naomi NPPEAG, Additio
Fineberg VIEWG nal

Biohaven. I have received research grants

From the UKRI, NIHR and Horizon Europe. I receive an honorarium from Elsevier for editorial duties for the journal comprehensive psychiatry. I am a board member of the consumer charity Orchard (registered

charity no:
1174480). I
have received
reimbursement
for personal
expenses for
giving lectures
at national and
international
meetings of
various
academic
bodies in non-
industry
sponsored
symposia.

Nashat Qamar	PEAG	Personal	NIL	N/A	N/A
Nashat Qamar	PEAG	Non-Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEW G	Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEW G	Non-Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEA G	Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEA G	Non-Personal	NIL	N/A	N/A

Nigel Stallard	HPMEWG	Personal	NIL	N/A	N/A
Nigel Stallard	HPMEWG	Non-Personal	Novartis	Support for icase PhD studentship	No
Nigel Stallard	HPMEWG	Non-Personal	Janssen	Support for icase PhD studentship	No
Nikoletta Fotaki	CPSEAG	Personal	NIL	NIL	N/A
Nikoletta Fotaki	CPSEAG	Non-Personal	NIL	NIL	N/A
Nikoletta Fotaki	CPSEAG	Additional			Director of Dr Fotaki BioPharm

Consulting (The Registrar of Companies for England and Wales- Company number: 13238377).

Patricia McGettigan	PEAG	Personal	NIL	N/A	N/A
---------------------	------	----------	-----	-----	-----

Patricia McGettigan	PEAG	Non-Personal	NIL	N/A	N/A
---------------------	------	--------------	-----	-----	-----

Patricia McGettigan	PEAG	Additional				I am an Independent Expert member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee
Patrick Holmes	CDRRA EAG	Personal	Daichii-Sankyo	Speaker Fees	Yes	
Patrick Holmes	CDRRA EAG	Personal	Boehringer Ingelheim	Speaker Fees	No	

Patrick Holmes	CDRRA EAG	Personal	Abbott	Speaker Fee and consultancy fee	No
Patrick Holmes	CDRRA EAG	Personal	Eli Lilly	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Personal	NovoNordisk	Consultancy Fee	No
Patrick Holmes	CDRRA EAG	Personal	AstraZeneca	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Personal	Dexcom	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Non-Personal	NIL	N/A	N/A

Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Consultancy	No
Patrick Mark	CDRRA EAG	Personal	Vifor	Lecture Fee	No
Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Clinical Trial Steering Committee, research funding	No
Patrick Mark	CDRRA EAG	Personal	Novartis	Trial End Point Committee (blinded)	No
Patrick Mark	CDRRA EAG	Personal	Boehringer Ingelheim	Lecture Fee	No

Patrick Mark	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Paul Dargan	CHM	Personal	NIL	N/A	N/A
Paul Dargan	CHM	Non-Personal	Moderna	PI within my hospital for COVID-19 vaccine study. All funding for this study came to my hospital.	No
Paul Dargan	CHM	Non-Personal	AstraZeneca	I am PI within my hospital for COVID-19 Study: A Phase I/III Randomized,	Yes

				Double-blind Study. All funding from this study comes to my hospital	
Paul Dargan	CHM	Non-Personal	Janssen	I am the PI within my hospital for the vaccine study. All funding for this study comes to my hospital.	Yes
Paul Dargan	CHM	Non-Personal	Atea	I was the UK CI for the Atea Phase 3 Randomized, Double-Blind, Placebo-Controlled Study	No

to Evaluate the Efficacy and Safety in High-Risk Outpatients with COVID-19. All funding for this study came to my hospital.

Paul
Dargan

CHM

Additio
nal

Chair of the
Royal College of
Emergency
Medicine and
National
Poisons
Information
Service Antidote
Guidelines

Group which oversees advice to hospitals in England for the stocking of antidotes; I have chaired this group since 2008. This group provides advice on the amount of antidote to be stocked by hospitals and the time-frame that the antidotes should

be available.
The advice is based on the published literature and there is no liaison with the pharmaceutical industry in relation to the guidance published by this group.

Paul
Dargan

CHM

Additio
nal

EAPCCT: I am
President of the
European
Association of

Poisons Control
Centres and
Clinical
Toxicologists
(EAPCCT:
<http://www.eapcct.org/>) from
May 2024 to
May 2025. The
EAPCCT is the
European
Clinical
Toxicology
Society and its
main role is to
organise the
annual
European

Paul
Dargan

CHM

Additio
nal

Toxicology
Conference
“with the specific
goal of
advancing
knowledge and
understanding of
the diagnosis
and treatment of
all forms of
poisoning”.

I am an expert
adviser on
clinical
toxicology to the
World Health
Organisation –

this has
predominantly
involved
advising on
issues in relation
to lead and
mercury
poisoning. In
recent years I
have contributed
to WHO
monographs
and guidelines
for lead and
mercury
poisoning.

Paul Dargan	CHM	Additional				I am on the Senior Editorial Board of Clinical Toxicology and the International Editorial Board of British Journal of Clinical Pharmacology.
Permindar Tony Singh Dhillon	OHEAG	Personal	Mount Alvernia PET CT Limited	Shares		Yes
Permindar Tony	OHEAG	Conferences/Scientific	Takeda	ESMO GI: Funding including flights,		No

Singh Dhillon		Meetin gs		accommodation and congress fees	
Permind er Tony Singh Dhillon	OHEAG	Confer ences/ Scienti fic Meetin gs	Servier	ESMO: Funding including flights, accommodation and congress fees	No
Permind er Tony Singh Dhillon	OHEAG	Non- Person al	NIL	N/A	N/A
Peter Buckle	HPMEW G	Person al	NIL	N/A	N/A

Peter Buckle	HPMEWG	Non-Personal	NIL	N/A	N/A
Peter Hall	RWDEWG	Personal	NIL	N/A	N/A
Peter Hall	RWDEWG	Non-Personal	AstraZeneca	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Eisai	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Roche	Received Institutional research funding	No

Peter Hall	RWDEWG	Non-Personal	Lilly	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Abbvie	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Novartis	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	MSD	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Gilead	Received Institutional research funding	No

Peter Hall	RWDEWG	Non-Personal	Sanofi	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	SeaGen	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	DxCover	Received Institutional research funding	No
Peter Pratt	ARMEWG	Personal	NIL	N/A	N/A
Peter Pratt	ARMEWG	Non-Personal	NIL	N/A	N/A

Member 2	VEEWG	Personal	NIL	N/A	N/A
Member 2	VEEWG	Non- Personal	NIL	N/A	N/A
Philip Hannafo rd	MWHEA G	Personal	NIL	N/A	N/A
Philip Hannafo rd	MWHEA G	Non- Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, HPMEW G	Personal	NIL	N/A	N/A

Poulam Patel	CHM, OHEAG, HPMEW G	Non- Person al	NIL	N/A	N/A
--------------	------------------------------	----------------------	-----	-----	-----

Poulam Patel	CHM, OHEAG, HPMEW G	Additio nal
--------------	------------------------------	----------------

I am a co-investigator on an Innovate UK research grant led by University of Nottingham with the SME's, Aqdot and Centillion as co-investigators

Ravishankar Sargur	GRIDEAG	Personal	NIL	N/A	N/A
Ravishankar Sargur	GRIDEAG	Non-Personal	NIL	N/A	N/A
Rebecca Kristeleit	OHEAG	Personal	Basilea	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Amphista	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Pharmamar	Consultancy and grant	Yes
Rebecca Kristeleit	OHEAG	Personal	Beigene	Grant	Yes

Rebecca Kristeleit	OHEAG	Personal	AstraZeneca	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Clovis	Consultancy and grants	Yes
Rebecca Kristeleit	OHEAG	Personal	Roche	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	GSK	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Eisai	Consultancy	No
Rebecca Kristeleit	OHEAG	Non-Personal	Various	Academic and Commercial Clinical Trial Programme with payments for trial	Yes

				work given to my Institution	
Reecha Sofat	PEAG	Personal	NIL	N/A	N/A
Reecha Sofat	PEAG	Non-Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Conferences/Scientific	AstraZenca, Sanofi	Sponsorship of conference - I was on the programme committee. Funding paid to EFGCP not to	No

Meetings

members of programme committee to pay for conference venue.

Rhian Thomas-Turner	PMEAG	Non-Personal	Sanofi	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Astellia	Team participation in Skipper (gilteritinib) and nephrology study CKD study	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Vertex	Team participation in delivering clinical trial	No

Rhian Thomas-Turner	PMEAG	Non-Personal	Noema Pharma	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Sobi	AVAPED study – team participation in delivering clinical trial.	No
Rhian Thomas-Turner	PMEAG	Non-Personal	EspeRare	Team participation in the EDELlife study.	No
Rhian Thomas-Turner	PMEAG	Non-Personal	MSD	Team participation in delivering clinical trial	No

Rhian Thomas-Turner	PMEAG	Non-Personal	X4 Pharmaceuticals	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Takeda	Team participation in delivering clinical trial	No
Richard FitzGerald	PEAG	Personal	NIL	N/A	N/A
Richard FitzGerald	PEAG	Non-Personal	NIL	N/A	N/A
Richard Gilson	IEAG	Personal	NIL	N/A	N/A

Richard Gilson	IEAG	Non-Personal	Gilead Sciences	My department is a collaborating site in clinical trials sponsored by Gilead Sciences, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	GSK	My department is a collaborating site in clinical trials sponsored by GSK	Yes

who have provided
research funds to
the department
(received by UCL
and by Central and
North West
London NHS
Foundation Trust).
I have been local
principal and
national chief
investigator on
multinational trials
sponsored by
GSK.

Richard Gilson	IEAG	Non-Personal	Janssen	My department is a collaborating site in clinical trials sponsored by Janssen, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	Merck	My department is a collaborating site in clinical trials sponsored by	Yes

Merck, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)

Richard
Gilson

IEAG

Non-
Person
al

Pfizer

My department is a collaborating site in clinical trials sponsored by Pfizer, who have provided research funds to the department

Yes

(received by UCL
and by Central and
North West
London NHS
Foundation Trust)

Richard
Gilson

IEAG

Non-
Person
al

ViiV

My department is
a collaborating site
in clinical trials
sponsored by ViiV,
who have provided
research funds to
the department
(received by UCL
and by Central and
North London NHS
Foundation Trust)

Yes

Richard Gilson	IEAG	Non- Person al	Procure Women Health Limited	Consultancy as Senior Scientific Advisor to Procure through a contract with UCL Consultants. All proceeds received by the UCL Institute for Global Health.	No
Member 1	VEEWG	Person al	NIL	N/A	N/A
Member 1	VEEWG	Non- Person al	NIL	N/A	N/A

Robert Andrews	HPMEW G	Person al	NIL	N/A	N/A
Robert Andrews	HPMEW G	Non- Person al	NIL	N/A	N/A
Robert Brown	VEEWG, HPMEW G	Person al	NIL	N/A	N/A
Robert Brown	VEEWG, HPMEW G	Non- Person al	NIL	N/A	N/A
Robert Lowe	CPSEAG, HPMEW G	Person al	NIL	N/A	N/A

Robert Lowe	CPSEAG, HPMEW G	Non- Person al	NIL	N/A	N/A
Robin Thorpe	CTBVEA G, HPMEW G	Person al	NIL	N/A	N/A
Robin Thorpe	CTBVEA G, HPMEW G	Non- Person al	NIL	N/A	N/A
Rod Mitchell	VEEWG	Person al	NIL	N/A	N/A

Rod Mitchell	VEEWG	Non-Personal	NIL	N/A	N/A
Rona Smith	CDRRA	Personal	Vifor Pharma	Honoraria	No
Rona Smith	CDRRA	Conferences/Scientific Meetings	GSK	European eGPA meeting: Expenses	No
Rona Smith	CDRRA	Non-Personal	GlaxoSmithKline	Clinical Study Grant	No

Rona Smith	CDRRA	Non-Personal	Union Therapeutics	Clinical Study Grant	No
Rubin Minhas	PMEAG	Personal	NIL	N/A	N/A
Rubin Minhas	PMEAG	Non-Personal	NIL	N/A	N/A
Rui Bebiano da Providencia e Costa	CHM	Personal	NIL	N/A	N/A

Rui Bebiano da Providen cia e Costa	CHM	Non- Person al	NIL	N/A	N/A	
Rupert Payne	PEAG	Person al	NIL	N/A	N/A	
Rupert Payne	PEAG	Non- Person al	NIL	N/A	N/A	
Rupert Payne	PEAG	Additio nal				I receive ongoing research funding from NIHR,

Rupert
Payne

PEAG

Additional

Wellcome and
MRC.

I was consultant
editor for the
journal
Prescriber
(Wiley
publishers) until
end 2024; this
journal carried
advertising from
the
pharmaceutical
industry,
although I was
not involved in

this aspect of
the journal.

Ruth Paulin	CPSEAG	Personal	NIL	N/A	N/A
Ruth Paulin	CPSEAG	Non-Personal	NIL	N/A	N/A
Sandosh Padmanabhan	CHM, CDRRA EAG	Personal	Kvatchii Limited	Founder shares	Yes
Sandosh Padmanabhan	CHM, CDRRA EAG	Non-Personal	NIL	N/A	N/A

Sarah Meredith	RWDEWG	Non-Personal	NIL	N/A	N/A
Sarah Meredith	RWDEWG	Personal	NIL	N/A	N/A
Sarah Wild	CDRRAEAG	Personal	NIL	N/A	N/A
Sarah Wild	CDRRAEAG	Non-Personal	NIL	N/A	N/A
Shahida Din	GRID EAG	Personal	Takeda	Speaker Fees	No
Shahida Din	GRID EAG	Conferences/Scienti	Janssen	European Crohn's & Colitis Annual Meeting	No

fic
Meetin
gs
Stockholm: Flights,
Accommodation,
Symposium
Registration Fees

Shahida Din	GRID EAG	Confer ences/ Scienti fic Meetin gs	Lilly	British Society of Gastroenterology annual meeting Birmingham: Registration, travel & accommodation support	No
----------------	-------------	--	-------	---	----

Shahida Din	GRID EAG	Confer ences/ Scienti fic	Helmsley Charitable Trust	Helmsley Charitable Trust Annual Gut Cell Atlas meeting New York: Registration, travel &	No
----------------	-------------	------------------------------------	---------------------------------	---	----

		Meetings		accommodation support	
Shahida Din	GRID EAG	Conferences/Scientific Meetings	AbbVie	United European Gastroenterology Week annual meeting Vienna: Registration, travel & accommodation support	No
Shahida Din	GRID EAG	Conferences/Scientific Meetings	AbbVie	Women in IBD meeting London: Registration, travel & accommodation support	No

Shahida Din	GRID EAG	Non- Person al	Edinburgh & Lothian Health Foundatio ns Award	Research funding	Yes
Shahida Din	GRID EAG	Non- Person al	Pathologi cal Society of Great Britain & Northern Ireland	Research funding	Yes
Shahida Din	GRID EAG	Non- Person al	Helmsley Charitable Trust: Gut Cell Atlas Normal &	Research funding	Yes

Crohn's
Disease

Shahida Din GRID EAG Non-Personal Helmsley Charitable trust Research funding Yes

Shahida Din GRID EAG Non-Personal Helmsley Charitable Trust Research funding Yes

Shahida Din GRID EAG Non-Personal AbbVie Research Fee to Unit Research and Development Fund as PI No

Shahida Din GRID EAG Additional Leadership Roles
1. British Society of

Gastroenterology
2019- to date
Inflammatory
Bowel Disease
Section
Committee
Member
2. Royal College
of Physicians of
Edinburgh 2020
to date
Gastroenterology
Specialty
Advisor
3. Scottish
Government
2021 to date
Lead for

Shahida Din GRID EAG Additional

Inflammatory
Bowel Disease -
Cancer
Surveillance

Collaborator for
Clinical Trial.
Funder: John
Moulton
Foundation
Sponsor: NHS
Lothian
/University of
Edinburgh

Principal (or
Sub)
Investigator for
Clinical Trial:

Shahida Din	GRID EAG	Additional				Current Trials Role Sub-PI Funder: Helmsley Charitable Trust Sponsor: King's College London
Shahida Din	GRID EAG	Additional				Role PI Funder AbbVie Sponsor AbbVie
Shahida Din	GRID EAG	Additional				Role Sub-PI Funder NIHR - HTA Sponsor: University of Birmingham
Shirley Price	PMEAG, HPMEW	Personal	NIL	N/A	N/A	

	G, VEEWG					
Shirley Price	PMEAG, HPMEW G, VEEWG	Non- Person al	GSK	Annual donation to the British Toxicology Society of which I am a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Yes	Please note I hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.

Shirley Price	PMEAG, HPMEWG, VEEWG	Non-Personal	AstraZeneca	Annual donation to the British Toxicology Society of which I am a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Yes	Please note I hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shirley Price	PMEAG, HPMEWG, VEEWG	Non-Personal	Apconix	Donation to the British Toxicology Society of which I am a Trustee for general support of	No	Please note I hold an Honorary Fellowships from the British Toxicology

the 2024 Annual Congress.
 The BTS is a charity and its Charity Registration No: 286197

Society and the UK Health Security Agency.

Shuaib Nasser	CDRRA EAG	Personal	Galderma	Consultancy	No
Shuaib Nasser	CDRRA EAG	Personal	ALK	Consultancy and lecture	No
Shuaib Nasser	CDRRA EAG	Non-Personal	NIL	N/A	N/A

Simon Drysdale	PMEAG	Personal	NIL	N/A	N/A
Simon Drysdale	PMEAG	Non-Personal	Janssen, AstraZeneca, Pfizer, Moderna, Valneva, GSK, MSD, iLiAD, MundiPharma and Sanofi	Consultancy and/or investigator roles (all fees paid to his institution)	Yes

Simon Drysdale	PMEAG	Non-Personal	MSD	Investigator Initiated research grants (all funds paid to my institution)	Yes
----------------	-------	--------------	-----	---	-----

Simon Drysdale	PMEAG	Additional			Member of the UK Department of Health and Social Care's (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) RSV subcommittee.
----------------	-------	------------	--	--	---

Siow-Ming Lee	OHEAG	Personal	NIL	N/A	N/A
Siow-Ming Lee	OHEAG	Conferences/Scientific Meetings	Roche	ESMO: Conference attendance, Transport and Registration Fees	No
Siow-Ming Lee	OHEAG	Non-Personal	NIL	N/A	N/A
Member 3	VIEWWG	Personal	NIL	N/A	N/A

Member 3	VIEWWG	Non- Person al	NIL	N/A	N/A
-------------	--------	----------------------	-----	-----	-----

Member 3	VIEWWG	Additional			I have an interest in the safe prescribing of valproate and developed and led an audit on the topic which has been published.
-------------	--------	------------	--	--	---

Stella O'Brien	MWHEA G	Person al	NIL	N/A	N/A
-------------------	------------	--------------	-----	-----	-----

Stella O'Brien	MWHEA G	Non- Person al	NIL	N/A	N/A
-------------------	------------	----------------------	-----	-----	-----

Stella
O'Brien

MWHEA
G

Additio
nal

Public voice
member of
CRUK (Cancer
Research UK)
Prevention,
Early Detection
& Diagnosis
Patient and
Public Panel
and International
Alliance for
Cancer Early
Detection
(ACED) Patient
and Public
Panel.
Standard NIHR
public
involvement

Stella
O'Brien

MWHEA
G

Additional

honorarium for
decision-making
activities.

Public member
of Surface
Sampling
Guidelines
Working Group
of HIS
(Healthcare
Infection
Society).
Standard NIHR
public
involvement
honorarium

Stella
O'Brien

MWHEA
G

Additional

Voluntary citizen
member of HTAi
(Health

Stella
O'Brien MWHEA G Additional

Technology
Appraisal
International),
no remuneration

Graduate of
their Patient
Research
Advocacy
program of
IASLC

Stella
O'Brien MWHEA G Additional

Public member
for the MHRA's
IDAP panel

Stella
O'Brien MWHEA G Additional

Public member
of Quality
Committee at
NHS England

Stella
O'Brien

MWHEA
G

Additional

Lay member of
Technical
Appraisal
Committee and
Expert Panels
for the
Diagnosis and
Management of
COVID-19 at
NICE. Public
member for
NIHR. Chair
Engagement
and Involvement
Committee
Standard NIHR
public
involvement
honarium.

Stella
O'Brien MWHEA G Additio
nal

Stella
O'Brien MWHEA G Additio
nal

Public member
of Public
Advisory Board
at the Our
Future Health
Chair of
Engagement
and Involvement
Committee at
THIS (The
Health
Improvement
Studies) Institute
Cambridge.
Standard NIHR
public
involvement
honorary.

Steven Cunningham	CHM, PMEAG	Personal	NIL	N/A	N/A
Steven Cunningham	CHM, PMEAG	Non-Personal	Gilead	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	ArkBiosciences	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No

Steven Cunningham	CHM, PMEAG	Non-Personal	Inhalon	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	Pfizer	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	Boehringer Ingelheim	Trial steering committee with employer fees paid	No

to the University of
Edinburgh.

Steven
Cunning
ham

CHM,
PMEAG

Additio
nal

01.24-03.24 I
was a member
of an EU IMI
research
consortium
(RESCEU to
9/22 now
PROMISE)
which had
Oxford
University and
Imperial College
as academic
partners.

Stuart H
Ralston

MWHEA
G

Person NIL
al

N/A

N/A

Stuart H Ralston	MWHEA G	Non- Personal	Abbvie	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Personal	Accord	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Personal	Amgen	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Personal	CSL Vifor	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Personal	Janssen	Support for scientific meeting	No

Stuart H Ralston	MWHEA G	Non- Person al	Eli-Lilly	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Person al	Novartis	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Person al	Thornton and Ross	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Person al	UCB	Support for scientific meeting	No
Stuart H Ralston	MWHEA G	Non- Person al	UCB	Consultancy to Institution	No

Stuart H Ralston	MWHEA G	Non-Personal	Angitia	Consultancy to Institution	No	
Stuart H Ralston	MWHEA G	Non-Personal	Kyowa Kirin	Support for recruiting patients into a clinical registry study	No	
Stuart H Ralston	MWHEA G	Non-Personal	Eli-Lilly	Donation of Teriparatide for a clinical trial	No	
Stuart H Ralston	MWHEA G	Additional				External examiner for Oxford University Clinical Trials MSc course, Jan

2024 - Nov
2024

Susan PEAG, Person NIL N/A N/A
Hunneyb ARMEW al
all G

Susan PEAG, Non- NIL N/A N/A
Hunneyb ARMEW Person
all G al

Susan PEAG, Additio
Hunneyb ARMEW nal
all G

I write articles published in the Chemist and Druggist magazine, a trade magazine for pharmacists but receive no payment for

those articles.
The information referred to is in the public domain. I make it clear that these are my personal views and reflections and references all sources of information used.

Susanna h Walsh	CPSEAG	Person al	Better Vision Solutions	Consultancy and licence agreement for technology. Named on patents.	Yes
--------------------	--------	--------------	-------------------------------	--	-----

Susanna h Walsh	CPSEAG	Person al	Chemical Biological Center of Combat Capabiliti es Developm ent Comman d and Defence Threat Reduction Agency	Research collaboration and MTA . Named on DMU Patents associated with work.	Yes
Susanna h Walsh	CPSEAG	Person al	Techfest	Director	Yes

Susanna Walsh	CPSEAG	Personal	University of Wolverhampton	External examiner (educational consultancy)	Yes	
Susanna Walsh	CPSEAG	Personal	Kingston University	External examiner (educational consultancy)	No	
Susanna Walsh	CPSEAG	Personal	Safer Disinfectant Network	I have attended some online meetings involving academics and disinfection companies run by the Safer Disinfectant Network. I have no personal links to	Yes	I have not attended a meeting for more than a year and am not sure if this organisation is still active.

the companies who are signed up to their charter (to promote best practice and support public health in the workplace) beyond those detailed above.

Susanna h Walsh	CPSEAG	Non- Person al	NIL	N/A	N/A
Sylvia Kama- Kieghe	MWHEA G	Person al	NIL	N/A	N/A

Sylvia Kama-Kieghe	MWHEA G	Conferences/Scientific Meetings	Theramex	Menopause Mentoring Programme/Course: Free course 3 x 1-hour sessions	No
Sylvia Kama-Kieghe	MWHEA G	Non-Personal	NIL	N/A	N/A
Tejal Mitchell	VIEWWG	Personal	GW Pharma	Honorarium for participating in educational symposium (non-promotional)	No
Tejal Mitchell	VIEWWG	Conferences/	UCB Pharma	DCEE educational event: Expenses	No

Scientific Meetings

(accommodation, meeting costs)

Tejal Mitchell	VIEWWG	Non-Personal	UCB Pharma	Sponsorship of Seizure Semiology and EEG course 2024	No
Tejal Mitchell	VIEWWG	Non-Personal	Angelini Pharma	Sponsorship of Seizure Semiology and EEG course 2024	No
Tejal Mitchell	VIEWWG	Non-Personal	Eisai	Sponsorship of Seizure Semiology and EEG course 2024	No

Tejal Mitchell	VIEWWG	Non-Personal	Micromed	Sponsorship of Seizure Semiology and EEG course 2024	No
Theresa McDonagh	CDRRA EAG	Personal	Boehringer Ingelheim	Fees for speaking / chairing at meetings	No
Theresa McDonagh	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Personal	NIL	N/A	N/A

Tom Clutton-Brock	HPMEWG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Additional			Director, Medical Devices Testing and Evaluation Centre Clinical Director, NIHR HealthTech Research Centre in Devices, Digital and Robotics Chair, NICE Interventional Procedures

Advisory
Committee
Associate
Medical
Director,
University
Hospitals
Birmingham
NHS Foundation
Trust
Professor of
Anaesthesia &
Intensive Care
Medicine,
University of
Birmingham,
Chair of the
interim Devices

Committee,
MHRA

Vanessa Raymont	CHM, VIEWG, ARMEW G	Person al	NIL	N/A	N/A
Vanessa Raymont	CHM, VIEWG, ARMEW G	Confer ences/ Scienti fic Meetin gs	Eisai	Promotional Meeting Optimising the Treatment of Early Alzheimer's Disease: A Collaborative Approach: Travel expenses to meeting	No

Vanessa Raymont	CHM, VIEWG, ARMEW G	Confer ences/ Scienti fic Meetin gs	Eisai	Podcast: Service Optimisation: Evolving Patient Pathways in AD	No
Vanessa Raymont	CHM, VIEWG, ARMEW G	Confer ences/ Scienti fic Meetin gs	IQVIA and Eli Lilly	Travel expenses to meeting	No
Vanessa Raymont	CHM, VIEWG, ARMEW G	Non- Person al	Janssen	Offer of potential funding for research study mainly funded by Medical Research	No

				Council grant for which I am Chief Investigator	
Vanessa Raymont	CHM, VIEWWG, ARMEWG	Non-Personal	Lilly	Staffing costs provided via a Collaborative Working Agreement to do a pilot project to expand CSF testing in NHS memory clinics for which I am Chief Investigator	No
Vanessa Raymont	CHM, VIEWWG,	Additional			I have acted as a local site Principal

ARMEW
G

Investigator for
commercial
clinical trials for
the following
companies:
ACI
Biogen
J and J
AriBio

Wajid Hussain	CDRRA EAG	Person al	NIL	N/A	N/A
Wajid Hussain	CDRRA EAG	Non- Person al	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Person al	NIL	N/A	N/A

Waqar Rashid	NPPEAG	Non- Personal	NIL	N/A	N/A
William Herrington	CDRRA	Personal	NIL	N/A	N/A
William Herrington	CDRRA	Non- Personal	Eli Lilly	Grant to the University of Oxford	Yes
William Herrington	CDRRA	Non- Personal	Boehringer Ingelheim	Grant to the University of Oxford	Yes
Member 5	VIEWG	Personal	NHS England	Salary	Yes

Member 5	VIEWWG	Non- Person al	NIL	N/A	N/A
William John Watkins	PMEAG	Person al	NIL	N/A	N/A
William John Watkins	PMEAG	Non- Person al	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Person al	NIL	N/A	N/A

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	CURIA	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Imperial College London	Research Collaborator: VaxHub Grant to University of Strathclyde.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in-kind research	No

support
(consumables).

Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	Avanti polar lipids/CR ODA	BBSRC Icase PhD studentship grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	AstraZen eca	PhD studentships including Icase.	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	Defence Threat Reduction Agency DTRA (administ	Research Grant to University of Strathclyde	No

ered by
DSTL)

Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	Janssen Pharmace utica	Research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	Target Healthcar e	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Person al	Takeda / Millenium Pharmace uticals	Knowledge exchange research contracts from company to	No

				University of Strathclyde	
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Precision Nanomedicines Inc	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of	No

				Strathclyde to support project.	
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	NOF CORPORATION	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore Technologies Ltd	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of	No

				Strathclyde. Innovate UK grant.	
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Personal	pHion	Innovate UK grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Personal	ABITEC	Joint PhD funding	No
Yvonne Perrie	CHM, CPSEAG, HPMEW G	Non- Personal	Centre for process Innovation Ltd	Research Grant to University of Strathclyde	No

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore ABITEC AstraZeneca Colorcon Croda	PhD CDT Training programme where I am Co-I. CMAC CEDAR	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Pfizer Sanofi Chiesi UCB Takeda Lilly Roche	Whilst not directly linked to my Nanomedicines theme in the PhD CDT programme, other companies are linked to the grant.	No
Yvonne Perrie	CHM, CPSEAG,	Additio nal			I am Head of Strathclyde Institute of Pharmacy and

HPMEW
G

Biomedical
Sciences
(SIPBS). We are
an
internationally
leading
technological
University and
as such we work
with many
companies
across the dept,
faculty and
University. We
also work with
Health care
providers
including a wide
range of NHS

Yvonne Perrie CHM, CPSEAG, HPMEWG Additio
nal

trusts and
pharmacies
through both
research and
education.

I am Head of
Strathclyde
Institute of
Pharmacy and
Biomedical
Sciences
(SIPBS). We are
an
internationally
leading
technological
University and
as such we work
with many

companies
across the dept,
faculty and
University. We
also work with
Health care
providers
including a wide
range of NHS
trusts and
pharmacies
through both
research and
education.

Contact information about these reports:

Medicines and Healthcare products Regulatory Agency
Customer Services
10 South Colonnade
Canary Wharf
London E14 4PU
Tel: 020 3080 6000
E-mail: info@mhra.gov.uk

© Crown copyright 2025

**Published by the Medicine and Healthcare products
Regulatory Agency**

ISBN 978-1-8384147-4-0

Guidance on reproducing and re-using MHRA Crown
copyright material can be found on our website at:

[http://www.nationalarchives.gov.uk/information-
management/re-using-public-sector-
information/copyright-and-re-use/crown-copyright/](http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/)

